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GST Glutathione S-transferase
h Hour
Ig Immuneglobuline
IL Interleukin
IDA Imino-diacetic acid
IPTG Isopropyl-β-D-thiogalactopyranoside
IRES Internal ribosome entry site
Jak Janus kinase
JH Jak-homology
kb Kilo base
kDa Kilo dalton
KIR Kinase inhibitory region
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MSCV Murine stem cell virus
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PCR Polymerase chain reaction
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pAB Polyclonal antibody
PEG Polyethylene glycol
pKi Isoelectric point
PVDF Polivinyldienedifluoride
pY Phosphotyrosine
R Receptor
RT Room temperature
RU Response unit
SDS Sodium-dodecylsulfate
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SHP SH2 domain-containing tyrosine phosphatase
SOCS Suppressor of cytokine signaling
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STAT Signal transducer and activator of transcription
Tab Table
TBS-T Tris-buffered saline-Tween-20
Thioredoxin TRX
Tris Tris(hydroxy)aminomethane
UV Ultraviolet
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1 Introduction
1.1 Role of Epo in hematopoiesis and clinical applications
Cytokines are a diverse group of soluble proteins and peptides which act as
humoral regulators of various immune- and non-immune functions. Erythropoietin
(Epo) (for review see 1), a 34 - 37 kDa protein, is mainly synthesized in the fetal
liver, shortly after birth there is a gradual shift of Epo production towards the
kidneys. Erythropoietin gene transcription is mainly regulated by the oxygen partial
Figure 1.1 Major steps in red blood cell differentiation and maturation. PPSC: Pluripotent stem cell,
CFU-GEMM: Colony-forming unit granulocyte erythrocyte monocyte macrophage, BFU-E: Burst-forming
unit erythroid, CFU-E: Colony-forming unit erythroid, RBC: Red blood cell.
pressure in the kidney and increases under hypoxic conditions. The sensor for
oxygen is located in the kidney and is supposed to be a heme-containing protein
since cobalt and nickel atoms, which can substitute the iron atom of heme mimic a
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EPO
IL-3, GM-CSF, EPO, IL-4
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IL-3, IL-6
G1
G0
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hypoxic state 2. Epo plays an important role in hematopoiesis. Hematopoiesis,
which comes from Greek „haima“ for blood and „poiein“, to make, is the
developmental process of the formation of new blood cells. In this context Epo is
responsible for differentiation of committed progenitor cells, as well as proliferation
and survival of erythroid precursors 3, 4. The most primitive precursor in this lineage
is the burst-forming unit erythroid (BFU-E, figure 1.1) which then differentiates into
the colony-forming unit erythroid (CFU-E). This maturation process is accompanied
by upregulation of Epo receptor (EpoR) expression and an increasing dependency
upon Epo. Each CFU-E can proliferate and differentiate into small colonies which
provide the basis for the differentiation into mature erythrocytes. The main clinical
use of Epo is the treatment of anemia resulting from severe kidney insufficiency.
Other important clinical uses of recombinant Epo are the treatment of anemia due
to chemotherapy or HIV infections. Moreover, Epo has been successfully applied in
pre-surgical activation of erythropoiesis, allowing the collection of autologous donor
blood 5. Recombinant Epo used for therapy is distributed by Amgen under the
brand name EPOGEN®.
1.2 Role of G-CSF in hematopoiesis and clinical applications
Granulocyte-colony stimulating factor (G-CSF) [reviewed in 6 is a 19.6 kDa
glycoprotein and is produced in activated monocytes, macrophages, neutrophils
and by stromal cells 7-9. G-CSF has great impact on hematopoiesis as it supports
the development of hematopoietic progenitor cells committed to the
neutrophil/granulocyte lineage 10. The importance of this cytokine has been
demonstrated by mice lacking G-CSF because of targeted disruption of the G-CSF
gene 11. These G-CSF -/- animals were shown to develop congenital chronic
neutropenia, granulocyte precursors were reduced by 50 % in bone marrow and the
granulopoietic response was severely decreased. When these mice were treated with
recombinant human G-CSF the symptoms caused by the lack of G-CSF
disappeared. Today the most important application of G-CSF is treatment of
leukopenias following bone marrow transplantations, chemotherapy or radiation
therapy, thereby increasing peripheral neutrophil blood counts 12-14. In several
studies the administration of recombinant G-CSF after chemotherapy reduced the
duration of infections which are often observed in patients with neutropenias.
Additionally, the dose of anti-tumor drugs can be enhanced when concomitantly
administered with G-CSF while the dosage of antibiotics can be reduced.
Improvements of hematological parameters have also been observed in the
treatment of patients with congenital neutropenia (Kostmann syndrome).
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Recombinant G-CSF used for therapy is distributed by different pharmaceutical
companies under the generic names Filgrastim® (Amgen) and Lenograstim® (Chugai
Pharmaceutical) as well as under the brand names Neupogen® (Amgen), Neutrogin®
(Chugai Pharmaceutical), and Granocyte® (Chugai Pharmaceutical).
1.3 Receptors of the hematopoietic receptor superfamily
Cytokines which are involved in the regulation of differentiation and proliferation of
blood cells are called hematopoietic cytokines. The respective receptors for these
Figure 1.2 The hematopoietic receptor superfamily
cytokines belong to the hematopoietic receptor superfamily 15, which can be further
subdivided into five families as shown in figure 1.2. Family 1 homo-dimerizes upon
stimulation, family two to four use a common beta (βc), gamma (γc) chain or gp130
as signaling subunit and those receptors which use two or more signaling subunits
belong to the interferon receptor family. General features of this superfamily include
a single extracellular ligand binding domain, four conserved Cys residues at the N-
terminus, a lack of cytoplasmic catalytic domains, box1 and box2 motifs, which are
required for mitogenesis 16 and, most importantly, cytoplasmic phosphotyrosine
residues which serve as recruitment sites for signaling and regulatory proteins
containing phosphotyrosine-binding domains such as Src homology (SH) 2
domains.
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1.4 Onset and down-regulation of signal transduction of homo-dimerizing
cytokine receptors with the EpoR as representative model
The inactivated EpoR is thought to be present in the plasma membrane as a
monomer although there is evidence for pre-formed, unliganded EpoR dimers 17, 18.
Upon binding of Epo, the receptor homo-dimerizes, resulting in the onset of
Figure 1.3 Initialization and down-regulation of Epo signal transduction
signaling cascades. In the first step the dimerization leads to autophosphorylation
of the receptor-associated Janus kinase Jak2 19 which then phosphorylate tyrosine
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residues within the cytoplasmic domain of the receptor, which, once
phosphorylated, serve as recruitment sites for a plethora of signaling molecules and
regulatory proteins. One important family of proteins which are recruited to the
EpoR and phosphorylated by Jak2, are the signal transducers and activators of
transcription (STATs) 5 molecules. The STAT5 molecules form homo-dimers upon
activation and translocate into the nucleus where they regulate gene expression.
Termination of Epo-mediated signal transduction is achieved either by receptor
internalization controlled by the proteasome 20 or by recruitment of regulator
proteins which associate with tyrosine residues within the receptor (fig. 1.3). In the
context of Epo signaling several proteins have been shown to down-regulate signal
transduction such as CIS, SOCS-3 or the phosphatase SHP-1.
1.5 SHP-1
The phosphatase SHP-1 (alternatively named HCP for hematopoietic cell
phosphatase, SHPTP-1 for SH2-containing phosphotyrosine phosphatase or PTP1C)
belongs to the group of non-transmembrane protein-tyrosine phosphatases (PTPs).
The enzyme contains one C- and one N-terminal SH2 domain (fig. 1.4), a catalytic
domain and a C-terminal tail of about 100 aa 21-23. For SHP-1 two splice variants
with 68 and 70 kDa, respectively, have been reported, whereas one variant is
predominantly expressed in hematopoietic tissue.
Figure 1.4 Schematic domain structure of SHP-1. SH2: Src homology 2 domain, PTPase:
Phosphotyrosine phosphatase domain.
So far two types of PTPs have been found, namely SHP-1 and SHP-2 24, with SHP-1
being usually a negative and SHP-2 a positive regulator of signal transduction 25.
SHP-1 plays a crucial role in the regulation of hematopoiesis, as shown by SHP-1
knock-out mice (me/me, mev/mev mice)26, 27. These mice lack the expression of
functional SHP-1 and in these mice hematopoietic cells hyper-proliferate in
response to growth factors which results in a dramatic overexpansion of
hematopoietic cells of different lineages. SHP-1 has been shown to directly associate
with the EpoR via its’ N-terminal SH2 domain and in parallel dephosphorylate Jak2
28. Moreover it was demonstrated that inhibition of SHP-1 expression by antisense
treatment enhanced hemoglobinization in SKT6 cells 29. Similarly to Epo, SHP-1 has
been shown to be induced by G-CSF in granulocytic differentiation, although a
SH2 PTPaseN CSH2
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direct association of the phosphatase and the G-CSFR could not be demonstrated
30. All these data emphasize the importance of SHP-1 in hematopoiesis. Therefore,
this protein represents a potential drug target an inhibitor of the phosphatase
would be expected to promote erythropoiesis and granulopoiesis.
1.6 SOCS proteins
Recently, a new family of inhibitors of cytokine signal transduction have been
described. According to their inhibitory action on signal transduction they were
named CIS - cytokine-inducible SH2 - containing protein or SOCS - suppressors of
cytokine signaling 31-34. CIS, as well as SOCS-1, SOCS-2 and SOCS-3 were cloned as
immediate-early genes induced by several cytokines which, once expressed,
participate in a negative feedback loop by inhibiting cytokine-mediated Jak/STAT
activation. It is assumed that SOCS proteins are regulated only at the
transcriptional level. SOCS-proteins share a central SH2 domain (fig. 1.5) which is
important for the interaction with phosphotyrosine residues of cytokine receptors
Figure 1.5 Schematic domain structure of SOCS proteins. KIR: kinase inhibitory region, ESS: extended
SH2 subdomain, SH2: Src homology 2 domain
and a C-terminal motif called the SOCS box 35 which is thought to be involved in
degradation of the protein by the ubiquitin-proteasome pathway 36, 37. The vital role
of SOCS proteins has been clearly demonstrated by the generation of transgenic
mice: SOCS-1 knock-out mice show perinatal lethality due to overproduction of
interferon γ  38, while mice lacking SOCS-3 reveal embryonic lethality associated
with marked erythrocytosis 39. Both Epo and G-CSF have been shown to induce
SOCS-3 mRNA and a direct association of SOCS-3 with the EpoR, together with
concomitant binding to Jak2 has recently been demonstrated 40. Although SOCS-3
has been shown to be induced by G-CSF in bone marrow cells 32 the role of this
regulatory protein in the context of G-CSF signal transduction has not been
elucidated so far.
1.7 SH2 domains
SH (Src homolgy) 2 domains are conserved, non-catalytic domains of approximately
100 amino acids in length. These domains are abundant in many proteins and
KIR
ESS SOCS Box
SH2N C
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function as adapter modules for recruitment to phosphotyrosine residues. Crystal
structures reveal that SH2 domains mainly consist of a β-sheet sandwiched by a
pair of α-helices. Via a highly conserved (positively charged) arginine residue the
SH2 domain contacts the negatively charged phosphotyrosine residue, thereby
pinning it into the binding pocket. Since many signaling pathways are regulated by
proteins possessing SH2 domains the interaction of specific SH2 domains with their
related phosphotyrosine motifs was suggested to be specific. Interaction studies
with SH2 domains and phosphopeptides revealed that there are preferences of
certain SH2 domains towards a given sequence of amino acids 41. Additionally, it
was demonstrated that critical positions for specific binding of SH2 domains to
phosphotyrosine motifs are the amino acids surrounding the phosphotyrosine
residues. The C-terminal amino acid residues at positions Y+1 to Y+5 of bound
peptides have been shown to be important for the interaction with SH2 domains,
with positions Y+1 and Y+3 having the greatest impact on the binding 42, 43.
1.8 Aims of this study
When binding to their receptors, growth factors trigger multiple signaling cascades
which finally result in transcription regulation of multiple target genes. Positive and
negative signal transduction pathways triggered by cytokines are equally important.
Down-regulation of cytokine-mediated signaling can be achieved in several ways
such as receptor internalization or by recruitment of inhibitory proteins which bind
to the growth factor receptor in a stimulation-dependent manner, thereby
attenuating signal transduction. This study focuses on the negative regulation of
both Epo and G-CSF signal transduction by the negative regulators SOCS-3 and
SHP-1. In order to better understand the action of these proteins in cytokine
signaling several approaches have been taken.
(1) From the literature it is known that both SHP-1 and SOCS-3 associate with
the EpoR after stimulation with Epo; while SHP-1 is constitutively expressed,
SOCS-3 mRNA is induced upon Epo stimulation (for schematic illustration see
figure 1.6).
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Figure 1.6 Schematic illustration showing the recruitment of SHP-1 and SOCS-3 to the EpoR
SHP-1 has been reported to bind to Y429 and Y431 whereas SOCS-3 has been
shown to bind to Y401 of the EpoR. Since it has been demonstrated that the
phosphatase SHP-2 competes with SOCS-3 for the phosphotyrosine 759 within
gp130, and, based on the observation that SHP-2 seems to have the same inhibitory
role in IL-6 signal transduction as it has been described for SHP-1 in the context of
Epo, it was proposed that a similar competition phenomenon between SOCS-3 and
SHP-1 44, 45 may be observed in Epo signal transduction (figure 1.5). To test this
hypothesis peptide precipitation assays, surface plasmon resonance studies as well
as molecular modeling were performed.
(2) Another aim of this study was the development of a biochemical high-
throughput screening assay for SHP-1 since this phosphatase is suggested to be an
important regulator of hematopoiesis and therefore an interesting target for the
pharmaceutical industry.
(3) Since no crystal structure of any SOCS protein has been published so far and
because human recombinant SOCS-3 was needed for SPR measurements, this
protein was expressed on a large scale. Crystal screening assays were set up by
DNA
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means of the hanging drop method in order to grow crystals for subsequent X-ray
diffraction studies at the EMBL in Grenoble.
(4) Finally, the role of SOCS-3 in G-CSF signaling was investigated. The induction of
SOCS-3 mRNA in bone marrow by G-CSF has been shown, however, the role of this
induction has not been previously investigated. In this study the role of SOCS-3 in
the context of G-CSF signal transduction was examined. In order to get more
insight into SOCS-3 mechanisms and actions in G-CSF signaling, biochemical as
well as cellular approaches were chosen.
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2 Material and Methods
2.1 Expendable items
2.1.1 Chemicals
All chemicals were of p.a. grade. Enzymes were mainly from New England Biolabs
(Frankfurt/Main, Germany), Roche (Mannheim, Germany) and Life Technologies
(Karlsruhe, Germany).
2.1.2 Antibodies and cytokines
Antibodies
Penta-His mAB (Qiagen, Hilden, Cat.# 34660) against 6x-His tags.
SOCS-3 mAB (Santa Cruz Biotechnologies, Heidelberg, Germany, Cat.#
sc-7009)
G-CSFR mAB (Research Diagnostics, Flanders, USA, Cat.# RDI-CD114-
LM)
STAT3 pAB (Cell signaling, Frankfurt, Germany, Cat.#9132)
Phosphotyrosine mAB Clone 4G10 (Upstate Biotechnology, Hamburg, Germany;
Cat.#05-321).
Sheep anti-mouse polyclonal serum raised against murine Ig. Horse radish
peroxidase-conjugated (Amersham Bioscience, Freiburg,
Germany; Cat.# NA931).
Donkey anti-rabbit polyclonal serum raised against rabbit Ig. Horse radish
peroxidase-conjugated (Amersham Bioscience, Freiburg,
Germany; Cat.# NA934).
Donkey anti-goat polyclonal serum raised against murine Ig. Horse radish
peroxidase-conjugated (Santa Cruz Biotechnologies, Heidelberg,
Germany, Cat.# sc-2020)
Cytokines
Epo human recombinant erythropoietin obtained from Zilaq
(Wuppertal, Germany, Cat.# Erypo FS 4000)
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G-CSF human recombinant G-CSF purchased from Stem Cell
Technologies (St. Katharinen, Germany, Cat.# 02615)
2.1.3 Plasmids and oligonucleotides
Prokaryotic expression vectors
pGEX-4-T1 Commercial expression vector from Amersham Pharmacia
Biotec. The gene of interest is under the control of a tac
promoter. GST 46 serves as fusion protein and affinity tag for
purification which can be cleaved by thrombin 47.
pET32a(+) Commercial expression vector from Novagen (Schwalbach,
Germany). Protein expression is under the control of a T7
promoter. Induction is achieved by addition of IPTG (1mM final).
Further features of this plasmid are a His® as well as a S tag®
for purification procedures, a β-lactamase gene for AMP®
resistance and the gene for TRX in order to enhance the
solubility of recombinant proteins 48. The fusion protein can be
cleaved of the protein of interest through thrombin or
enterokinase.
pET29a(+) Successor of pET28a. Lacks TRX and S tag. Kanamycin
resistance
pET30a(+) Predecessor of pET29a. Lacks TRX tag. Kanamycin resistance.
pMYZ316 pET32a vector with human SHP-1 C-terminally fused to TRX.
pMYZ340 pGEX-4-T1 vector with human SHP-1 in a C-terminal fusion
with GST.
pMYZ372 pET32a vector with human SOCS-3 fused C-terminally to TRX.
pMYZ470 pET32a vector with human SOCS-3 lacking the first 22 amino
acids, fused C-terminally to TRX.
Eukaryotic expression vectors
pMYZ325 pcDNA 3.1 construct containing G-CSFR
pMYZ387 pMYZ404 containing the cDNA of human SOCS-3
pMYZ399 pcDNA 3.1 luciferase reporter plasmid containing six identical
repeats of the STAT1, STAT3, STAT4 and STAT5 DNA binding
motif TTCnnnGAA 49, spaced by 13 nucleotides, respectively.
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pMYZ404 Retroviral vector with a MSCVneo (Clontech, Heidelberg,
Germany) backbone with the MCS of Bluescript II KS(+), an
internal ribosome entry site (IRES), and a green fluorescent
protein (GFP)-Zeocin fusion protein (constructions details see
2.18).
pMYZ479 pcDNA 3.1 construct containing a G-CSFR mutant where Y729
was substituted with F
pMYZ480 pcDNA 3.1 construct containing a G-CSFR mutant where Y704
was substituted with F
pMYZ515 pcDNA 3.1 construct containing hSOCS-3 with a G53V
mutation in the SH2 domain
pMYZ516 pcDNA 3.1 construct containing hSOCS-3 with a L58A mutation
in the SH2 domain
pMYZ518 pcDNA 3.1 construct containing hSOCS-3 with a L93A mutation
in the SH2 domain
pMYZ519 pcDNA 3.1 construct containing hSOCS-3 with a R94E
mutation in the SH2 domain
pMYZ523 pcDNA 4HisMaxC containing the cDNA hSOCS-1
Oligonucleotides
All oligonucleotides were purchased from Life Technologies (Karlsruhe, Germany).
2.1.4 Prokaryotic cells
For conventional cloning purposes Subcloning Efficiency DH5α™ E.coli (Life
Technologies, Karlsruhe, Germany) were used. This strain lacks among other things
the endAI-Gene, a nonspecific Endonuclease I; DNA preparations are thought to be
of higher quality when prepared from endA strains. For protein expression
BL21(DE3)-CodonPlus-RIL and BL21(DE3)-CodonPlus-RP E.coli strains were used
(Stratagene, Heidelberg, Germany). Bacteria of the BL21 strain lack genes for two
proteases (lon, ompT) which can cause rapid degradation of the target protein.
BL21(DE3)-CodonPlus-RIL cells carry extra copies of the argU, ileY, and leuW tRNA
genes. The tRNAs encoded by these genes recognize the AGA/AGG, AUA, and CUA
codons, respectively. This modification allows high-level expression of proteins that
are difficult to express in conventional E.coli hosts due to the codon bias of the gene
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of interest. BL21-CodonPlus-RP cells contain a ColE1-compatible plasmid that
encodes extra copies of the argU and proL tRNA genes and is able to rescue
expression of genes restricted by either AGG/ AGA codons or CCC codons.
Therefore these cells are ideal for expression of GC-rich DNA sequences.
2.1.5 Eukaryotic cells
HEK 293 adherent cells derived from human embryonic kidney (ATCC,
CRL-1573)
U937 suspension cells; monocytic precursor cell line (ATCC, CRL-
1593.2)
EcoPhoenix adherent ecotropic cells for virus production based on 293T
cells. Cells were used in agreement with H. Hanenberg,
University of Düsseldorf.
PG13 adherent cells derived from NIH/3T3 cells stably transfected
with the gene of the Gibbon ape leukemia virus envelope. These
cells can be used for virus production (ATCC, CRL-10686).
COS-7 adherent cells derived from monkey kidney (ATCC, CRL-1651)
293T adherent cells derived from human embryonic kidney (ATCC,
CRL-1573) stably carrying the large T-antigen cDNA.
2.1.6 Peptides and proteins
Biotinylated and FITC-labeled peptides were purchased from PolyPeptide
Laboratories (Martinsried, Germany) or Jerini Biotools (Berlin, Germany).
Recombinant PTP-1B was purchased from Biomol (Biomol, Hamburg, Germany;
Cat# SE-332).
2.2 General protocols for molecular biology
2.2.1 Transformation of chemically competent E.coli cells
50 µl of bacteria were mixed with 500 pg - 1 ng of plasmid DNA and  placed on ice
for 10 min. Heat shock was performed at 42°C in a water bath for 1 min 30 sec;
after that bacteria were immediately placed on ice for further 10 min, then 1 ml LB-
medium was added and the cells were shaken at 225 rpm on a thermal block for
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40 min. Finally cells were sedimented at 4,000 g and plated on agar plates
containing the appropriate antibiotic.
2.2.2. Isolation of plasmid DNA
8 ml, 100 ml and 500 ml overnight cultures of plasmid carrying bacteria were
harvested and the DNA was isolated according to the manufacturer’s instructions
(Macherey & Nagel, Düren, Germany). DNA preparations from 8 ml cultures were
made for cloning control purposes, 100 and 500 ml preparations were preparative
DNA isolations. Isolated DNA was dissolved in 10 mM Tris/HCl, pH 8.0.
2.2.3 Quantitative analysis of nucleic acids
Quantitation of nucleic acids was done with a UV spectrometer (Eppendorf,
Hamburg, Germany), measuring the absorption at 260 nm. One unit of absorption
corresponds to 50 µg dsDNA. The purity of nucleic acids can be determined by
measuring the sample at 260 and 280 nm, respectively. The quotient of A260/A280
should be in the range of 1.7-2.0.
2.2.4 Digestion of DNA with restriction endonucleases
Digestion of DNA was performed according to standard instructions 50. Reaction
conditions were adapted to the manufacturer’s instructions for the particular
enzyme(s) used. Incubation times varied between 1 and 4 hours, depending on the
cutting properties of the enzyme and the amount of DNA.
2.2.5. Dephosphorylation of linearized DNA
In order to prevent re-ligation of vector DNA without insert the terminal 5‘-
phosphate was removed by treatment with calf intestine phosphatase (CIP; NEB,
Frankfurt/Main, Germany). Generally, 400-500 ng DNA were digested with 0.5 U
CIP at 37°C for 60 min, as proposed by the manufacturer. After incubation the DNA
fragments were gel-purified.
2.2.6 Ligation of DNA
Ligation of dsDNA was performed with T4 DNA ligase (NEB, Franfurt/Main,
Germany). Vector and Insert were added at ratios of 10:1, 1:1 and 1:10,
respectively. For increased ligation efficiency PEG2000 was added to a final
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concentration of 5 %. The ligation reaction was incubated at 20°C for 1-2 hours.
After ligation competent bacteria were transformed with the ligated DNA.
2.2.7 Separation of DNA fragments by agarose gel electro-
phoresis
DNA samples were mixed with 6× DNA sample buffer (final concentration 1×) and
loaded on an agarose gel (SeaKem-LE agarose, Biozym; Hameln, Germany). The
percentage of the agarose in the gel used depended on the size of the fragments to
be isolated. The higher the molecular weight of the fragment the lower the
percentage of agarose used. Molecular masses of DNA fragments were determined
by using DNA mass standards. After melting the agarose 0.2 µg/ml Ethidium
bromide was added to the gel. Ethidium bromide is a fluorogenic dye which
intercalates with DNA. This stain makes DNA visible under UV light.
6x DNA loading buffer: 40% (w/v) sucrose in water
0.5% (w/v) Orange G (Sigma #O1625)
50x TAE buffer: 242 g Tris Base
57 ml Acetic acid
100 ml EDTA 0.5M, pH 8.0
ad 1 l H2O
2.2.8 Isolation of DNA fragments from agarose gels
DNA fragments obtained after PCR or restriction reaction were separated on an
agarose gel, excised with a scalpel and extracted with the QiaEX II kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions. DNA was eluted
with H2O or 10 mM Tris/HCl, pH 8.0.
2.2.9 Polymerase chain reaction (PCR)
All constructs were produced by PCR techniques. Synthetic oligonucleotides which
were complementary to the sequence of the templates were used as primers for Pfx
polymerase. Pfx polymerase synthesizes approximately 1,000 bases per minute.
Therefore, the extention time was adjusted in each PCR to the template length. In
the case of SHP-1 (1.8 kb) the extention time was 2 min and for SOCS-3 (600 bp)
40 sec.
PCR mix: 10 ng DNA (template)
25 pmol Primer1
25 pmol Primer2
1.5 µl dNTPs (final conc. 0.3M each)
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1.25 U Pfx polymerase
5 µl 10x PCR buffer
1 µl MgSO4 (final 1mM)
ad 50 µl H2O
Reaction cycles: 5 min 94°C enzyme activation
1 min 94°C first denaturation
1 min 60°C primer annealing × 30 cylces
var time 72°C primer extention
10 min 72°C final extention
2.2.10 Automated DNA sequencing
The principle of automated DNA sequencing is based on excitation and detection of
fluorescent didesoxynucleotides which terminate DNA synthesis 51 and in parallel
label the DNA at different locations by means of a PCR. Sequencing was done
externally at Invitec Corp. (Berlin, Germany).
2.2.11 PCR mutagenesis
PCR mutagenesis was performed using the QuikChange® mutagenesis kit (Strata-
gene, Heidelberg, Germany) according to the manufacturer's recommendation.
2.3 General protocols for biochemistry and
immunology
2.3.1 Isolation of proteins from bacteria
Bacteria were grown in LB-media with 100 µg/ml ampicillin. After induction with a
final concentration of 1 mM IPTG cells were grown for further 5 hours at either
37°C (SHP-1) or 25°C (SOCS-3). Sedimented bacteria were resuspended in lysis
buffer. After resuspension final concentrations of 10 µg/ml DNaseI, 10 µg/ml
lysozym and 0.1 % Triton X-100 were added. Additionally, a protease inhibitor
cocktail tablet (Roche, Mannheim, Germany; Cat.# 1873580) was added to the
solution. Lysed cells were sonicated two times for 1 min, respectively, and
centrifuged at 70,000 × g at 4°C for 1 h. After decanting the supernatant the pellet
was again resuspended in denaturating lysis buffer to solubilize possible inclusion
bodies. This „insoluble“ lysate was again centrifuged for 1 hour at 70,000 × g at RT.
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All fractions were then loaded onto a SDS-PAGE and analyzed for the recombinant
protein.
Lysis buffer: 50 mM Tris/HCl, pH 8.0
10 % (w/v) Glycerol
60 µg/ml Antipain-HCl
10 µg/ml Bestatin
0.1 U/ml Chymostatin
60 µg/ml E-64
10 µg/ml Leupeptin
10 µg/ml Pepstatin
60 µg/ml Posphor-amidone
400 µg/ml Pefabloc
10 µg/ml Aprotinin
Denaturating lysis buffer:
50 mM Tris/HCl, pH 8.0
6 M GdnCl
2.3.2 SDS-PAGE
Protein separation under denaturating conditions was done according to the
method of discontinuous electrophoresis of Laemmli 52. Electrophoresis was
performed in a vertical electrophoresis chamber at 100 V until the dye front reached
the separating gel, then at 200 V for 30 min at RT. Samples were mixed with 2×
Laemmli-buffer, heated for 5 min at 99°C, cooled down on ice and then centrifuged
at 14,000 × g for 1min before loaded on the gel. Molecular size marker were either a
low or a high molecular weight standard from Biorad (Biorad, Munich). Precast gels
(10 % Acrylamide) were purchased from Invitrogen (Invitrogen, Renfrewshire,
Scotland).
SDS running buffer: 50 mM MES
50 mM Tris/HCl (pH 7.3)
3.5 mM SDS
1 mM EDTA
ad 1 l H2O, pH 7.3
2× Laemmli buffer: 100 mM Tris/HCl (pH 6.8)
200 mM DTT
4 % (w/v) SDS
0.2 % (w/v) Bromphenol blue
20 % (w/v) Glycerol
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2.3.3 Staining of proteins
Coomassie staining
With the Coomassie® Brilliant Blue detection method for proteins amounts down to
100 ng can be detected. The principle of this staining method is based on the
unspecific lipophilic association of the dye with the proteins. Immediately after
electrophoresis SDS gels were placed into Coomassie® solution, warmed in a
microwave oven for 30 sec to about 50°C and then agitated for 30 min at RT. Then
the staining solution was replaced by the destain solution, again warmed for 30 sec
in a microwave oven and then shaken for 1 - 2 hours at RT.
Coomassie stain: 2,5 g Coomassie Brilliant Blue R250™
900 ml Ethanol/H2O (1:1 v/v)
100 ml Acetic acid
Destain solution: 30 % (w/v) Methanol
10 % (w/v) Acetic acid
Sypro Red staining
As an alternative to Coomassie Blue the fluorescent SYPRO® Red protein gel stain
was used. SYPRO Red is more sensitive than Coomassie®, with a detection limit
between 1-10 ng of protein. For staining the gel was incubated for 30-60 min in
staining solution at room temperature. Then the gel was shortly washed with 7.5 %
acetic acid and analyzed with the ImageMaster® VDS system (Amersham
Bioscience, Freiburg, Germany).
2.3.4 Quantitation of proteins
Determination of protein amount by the method of Bradford
The concentration of protein solutions was determined with the Coomassie® Plus
Protein Assay Reagent (Pierce, Bonn, Germany). 5 µl of protein solution were mixed
with 995 µl of Coomassie® reagent and after 3 minutes incubation the OD595 was
measured in a photometer. A standard curve with BSA ranging from 125 µg/ml to
2 mg/ml served as reference for determination of the protein concentration.
Determination of protein amount with the method of Edelhoch
Protein concentration of pure proteins was determined by the method of Edelhoch
53, over an absorption spectrum of 240-340 nm.
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2.3.5 Buffer change of protein solutions
Protein solutions were either dialyzed using cellulose membrane dialysis tubings
(Roth, Karlsruhe, Germany). The molecular weight cut-off volume was adjusted to
the protein size. Dialysis was performed in a 500 to 10,000-fold volume of the
protein sample at 4°C. Another method used for buffer exchange was gel filtration
by means of pre-packed HiTrap Desalting columns (Amersham Bioscience,
Freiburg, Germany).
2.3.6 Western blot
For immunological detection of proteins SDS-PAGEs were transferred onto PVDF
membranes (Stratagene, Heidelberg, Germany) by means of a semi-dry blotting
system (Biorad, Munich, Germany). Electrotransfer was performed at room
temperature for 30 min at 0.2 mA/cm2.
Transfer buffer: 25 mM Tris/HCl
192 mM Glycine
200 ml MeOH
ad 1l H2O
pH 8.3
After protein transfer, membranes were shortly swayed in methanol, equilibrated for
5 min in TBS-T, then blocked with 5 % BSA for 1 h at RT. After blocking, the
membranes were washed three times for 5 min with TBS-T, then shaken in a
solution containing the primary antibody (1 h, RT). Amounts of antibody were
chosen according to the manufacturer’s recommendations. After three 5 min
washes with TBS-T, the HRP-conjugated secondary antibody (usually diluted
1:10,000) was added for 1 h at RT. Detection of the antigen-antibody complex was
done with the ECL system from Amersham Bioscience. The chemoluminescent
signal was visualized on an autoradiography film.
2.3.7 Concentration of protein solutions
Protein solutions were concentrated with Ultrafree-15 Centrifugal Filter Units
(Millipore, Eschborn, Germany) with vertical filter membranes according to the
manufacturer’s instructions. Size exclusion limits were adjusted to the molecular
weight of the protein.
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2.3.8 Cleavage of fusion proteins with proteases
Thioredoxin-fusion proteins which had to be cleaved from the protein of interest
were incubated with a protease. Plasmids used for prokaryotic protein expression
coded for an enterokinase (Roche, Mannheim Germany) cleavage site between
thioredoxin and the initiation codon of the gene of interest. Digestion assays were
performed according to the manufacturer’s instructions.
2.4 Chromatography
2.4.1 ÄKTA system
For protein purification an ÄKTA™ purifier 100 system (Amersham Bioscience,
Freiburg, Germany) was used. The ÄKTA system consisted of four P-903 pumps, an
UV flow cell UV-900, a pH electrode, a conductivity flow cell C-900, a mixer M-925
and a fraction collector Frac-901. Chromatograms were analyzed using the
UNICORN™ software package version 3.0 (Amersham Bioscience, Germany).
Operating temperature was 4°C. All columns used were exclusively from Amersham
Bioscience.
2.4.2 Affinity chromatography
For affinity purification of proteins pre-packed „HiTrap chelating“ 5 ml columns,
with imminodiacetic (IDA) acid as ligand were used. To enhance binding capacity of
the apparatus two 5 ml columns were connected to give double bed volume.
Proteins were eluted with an imidazole gradient, the maximal concentration for
imidazole was 500 mM. Loading of the column was performed with 17 mM
imidazole to reduce unspecific binding of protein.
Buffer A: see section 2.3.1
Buffer B: 50 mM Tris/HCl (pH 8.0)
10 % (w/v) Glycerol
500 mM Imidazole
2.4.3 Ion exchange chromatography (IEX)
Following affinity selection, depending on the protein’s properties (i.e. pKI), either
cationic or anionic exchange chromatography was chosen for further protein
purification 54. In the case of cationic exchange chromatography „HiTrap SP“ 5 ml
columns, for anionic exchange purposes „MonoQ“ or „HiTrapQ“ columns with a bed
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volume of 0.9 and 5 ml, respectively, were used. Columns were equilibrated with 4
column volumes (CV) of buffer A, then flushed with 2 CV of buffer B and then again
flushed with 4 CV of buffer A, whereas buffer A was always the low salt buffer. The
target protein was eluted with a NaCl gradient. Buffers for anionic exchange
chromatography of SOCS-3 were:
Buffer A: 50 mM Tris/HCl, pH 8.5
10 mM DTT
0.1 % (w/v) NaN3
Buffer B: 50 mM Tris/HCl, pH 8.5
1 M NaCl
10 mM DTT
0.1 % (w/v) NaN3
2.4.4 Gel filtration
Gel filtration 55 was performed with a „HiLoad Superdex 75 26/60“(pre-packed),
„Sephacryl S-300HR 26/100“, „HiTrap Desalting“, or „PD10“ column. The first two
columns were used for separation of proteins, the other two columns for buffer
exchange. Generally, columns were equilibrated with 4 CV of appropriate buffer.
Flow rates were adjusted according to the manufacturer’s instructions. The „HiLoad
Superdex 75 26/60“ and „Sephacryl S-300HR 26/100“ column were calibrated with
a commercially available kit (Amersham Bioscience), containing ribonuclease A
(13.7 kDa), chymotrypsinogen (25 kDa), ovalbumin (43 kDa), bovine serum albumin
(67 kDa) and Blue Dextran 2000 (≈2000 kDa). Blue Dextran served to determine the
void volume and to check the packaging of the columns. Gel filtration buffers for
SHP-1 and SOCS-3 were:
SHP-1 buffer: 50 mM Tris/HCl, pH 7.2
150 mM NaCl
10 mM DTT
0.1 % (w/v) NaN3
SOCS-3 buffer: 50 mM Tris/HCl, pH 7.5
150 mM NaCl
10 mM DTT
0.05 % (w/v) CHAPS
0.1 % (w/v) NaN3
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2.5 Cloning of expression vectors for human SHP-1
and SOCS-3
2.5.1 Expression vectors for SHP-1
The search for the cDNA sequence of human SHP-1 was performed in GenBank, a
database for nucleotide and proteins of the NIH, at: http://www.ncbi.nlm.nih.gov/.
The database search revealed three independent gene names 22, 23, 56, coding for the
protein SHP-1 (Swiss-PROT: P29350), respectively. Subsequently, a BLAST-search
57 against dbEST was performed and several EST clones corresponding to the cDNA
sequence of SHP-1 were selected for PCR cloning. Flanking primers containing sites
for NotI and EcoRI were as follows:
sense: 5‘-TTT AAA TTT GCG GCC GCA TGG TGA GGT GGT TTC ACC GAG ACC
antisense: 5‘-TTT AAA TTT GAA TTC TCA CTT CCT CTT GAG GGA ACC CTT
The fragment of SHP-1 was cloned in pBluescript II KS(+) (Stratagene, Heidelberg,
Germany), sequenced and then subcloned (NotI/EcoRI) into pET32a (+) and pGEX-
4-T1. These constructs were named MYZ316 and MYZ340, respectively.
2.5.2 Expression vectors for SOCS-3
The cDNA for human SOCS-3 was obtained by searching the non-redundant
database of EST clones at http://www.ncbi.nlm.nih.gov/. EST#725896 was taken
as template for a PCR with flanking primers containing restriction sites for BamHI
and EcoRI, respectively. The sequences of the primers were:
sense: 5‘-AAA TTT AAA GGA TCC ATG GTC ACC CAC AGC AAG TTT CCC GCC
antisense: 5‘-AAA TTT AAA GAA TTC ATT AAA GCG GGG CAT CGT ACT GGT CCA G
The PCR fragment of SOCS-3 was cloned into pBluescript II KS(+) (Stratagene,
Heidelberg, Germany), sequenced and then subcloned into pET32a. The plasmid
was named pMYZ372.
A truncated mutant of SOCS-3 lacking the first 22 at the N-terminus was generated
by mutation PCR by means of the QuikChange® mutagenesis kit (Stratagene,
Heidelberg, Germany). The sequence of the deletion primers were:
sense: 5‘-TAC CGA CGA CGA CGA CAA GAA GAC CTT CAG CTC CAA GA
antisense: 5‘-TCT TGG AGC TGA AGG TCT TCT TGT CGT CGT CGT CGG TA
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Template for mutagenesis was pMYZ372, the new plasmid containing truncated
SOCS-3 was named pMYZ470.
SOCS-3-SH2 domain mutants were generated using the Quikchange mutagenesis
kit (Stratagene, Heidelberg, Germany) according to the manufacturer's
recommendations. Mutagenesis primers were as follows:
5‘-CTACTGGAGCGCAGTGACCGTCGGCGAGGCGAACCTGCTGC-3‘ (G53V sense),
5‘-GCAGCAGGTTCGCCTCGCCGACGGTCACTGCGCTCCAGTAG-3‘ (G53V anti-
sense), 5‘-GACCGGCGGCGAGGCGAACGCGCTGCTCAGTGCCGAGCCCG-3‘ (L58A
sense), 5‘-CGGGCTCGGCACTGAGCAGCGCGTTCGCCTCGCCGCCGGTC-3‘ (L58A
antisense), 5‘-CAGTCTGGGACCAAGAACGCGCGCATCCAGTGTGAGGGG-3‘ (L93A
sense), 5‘-CCCCTCACACTGGATGCGCGCGTTCTTGGTCCCAGACTG-3‘ (L93A
antisense), 5‘-GTCTGGGACCAAGAACCTGGAAATCCAGTGTGAGGGGGGCAGC-3‘
(R94E sense), 5‘-GCTGCCCCCCTCACACTGGATTTCCAGGTTCTTGGTCCCAGAC-3‘
(R94E s).
2.6 Expression and purification of SHP-1
The expression of human SHP-1 was performed in E.coli of the BL21(DE3) strain.
Experimental procedures were done according to the manufacturer’s
recommendations (Novagen, Schwalbach, Germany). 500 ml of pre-warmed LB-
medium was inoculated 1:50 from an overnight culture, grown until a OD600 of 0.8,
induced with final 1 mM IPTG. Protein expression was performed for 5 hours at
37°C. Purification of SHP-1 was done as described in section 2.4.2., purity of the
protein was monitored by SDS-PAGE.
2.7 Expression and purification of SOCS-3
Human SOCS-3 was expressed in BL21(DE3)-RIL codon plus E.coli (see section
2.1.4). 500 ml of pre-warmed LB-medium was inoculated 1:50 from an overnight
culture, grown until a OD600 of 0.5, then cooled down to 25°C. At an OD600 of 1 to
1.1 bacteria were induced with final 1 mM IPTG and protein expression was
performed for 5 hours at 25°C. Purification of SOCS-3 was performed as described
in section 2.4.2, 2.4.3 and 2.4.4. For Biacore measurements SOCS-3 was purified
by affinity chromatography and consecutive anionic exchange chromatography. For
crystallization experiments SOCS-3 was affinity-purified (2.4.2), digested with
enterokinase (2.3.8), purified by cationic exchange chromatography (2.4.3), gel
filtrated (2.4.4) and in a final step concentrated by centrifugation (2.3.7).
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2.8 Binding of SOCS-3 to biotinylated phospho-
peptides
Binding of SOCS-3 to phosphorylated peptides was detected by means of a peptide
precipitation assay. Approximately 0.5 µmoles of biotinylated peptides were coupled
to 2.5 mg Streptavidin Sepharose (Amersham Bioscience, Freiburg, Germany),
washed twice with wash buffer and then incubated at 4°C for at least 3 hours on an
overhead shaker with either cell lysates containing overexpressed SOCS-3 or
approximately 5 µg of purified recombinant SOCS-3. After incubation the
precipitate was washed three times at 4°C with wash buffer and finally resuspended
in 30 µl 2× Laemmli buffer. Samples were then incubated for 10 min at 95°C, run
on a polyacrylamide gel and transferred onto a PVDF membrane (Stratagene,
Heidelberg, Germany) for subsequent Western blot analyses (2.3.6). A goat anti-
SOCS-3 polyclonal antibody was used as a secondary antibody.
Wash buffer: 25 mM Tris/HCl
75 mM NaCl
5 mM Sodium orthovanadate
0.25 % Triton X-100
0.25 % NP-40
30 µg/ml Antipain-HCl
50 µg/ml Bestatin
0.05 U/ml Chymostatin
30 µg/ml E-64
5 µg/ml Leupeptin
5 µg/ml Pepstatin
30 µg/ml Posphor-amidon
200 µg/ml Pefabloc
5 µg/ml Aprotinin
pH 7.5
2.9 Measurement of protein interactions by surface
plasmon resonance (SPR)
2.9.1 Principle
SPR is a method to analyze interactions between macromolecules in real time which
can be used for kinetic analysis, affinity measurements, competition studies and
many other applications 58. This method relies on the phenomenon of surface
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plasmon resonance, which occurs upon the interaction of monochromatic light with
a metal surface, i.e. silver or gold, under conditions of total internal reflection 59.
This total reflection is used to excite nonradiative surface plasmons in the metal
film. Surface plasmons are waves of oscillating surface charge density travelling
along the metal surface. These plasmons can be resonantly excited by light only
when the wave vector of the light in the plane of the sensor surface matches that of
the surface plasmon. The resonance causes an energy loss in the reflected light
which has an influence on the angle-dependent reflectance of the metal surface.
The metal is coated with a hydrophilic matrix (mostly dextran) on which one of the
interaction partners is immobilized. The other binding partner is injected over this
surface and, as binding occurs, the refractive index of the medium is increased and
the resulting change in the angle of reflection is recorded 60. This response is
converted to arbitrary resonance units (RUs) with 1 RU corresponding to ~1 pg
protein mm-2. Time resolutions up to ~0.1 s can be achieved. The experiments were
performed using a BIAcore3000™ instrument, the BiaEvaluation™ software
Ver.3.0.1 was used for data analyses.
2.9.2 Measurement of SOCS-3 with biotinylated peptides
Biotinylated peptides were loaded on a streptavidin (SA)-coated biosensor chip
(Biacore, Freiburg, Germany). Before loading of the sensor chip with peptide the
surface was washed three times for 30 sec with 1 M NaCl in 50 mM NaOH. Peptides
(100 ng/ml) were loaded onto the chip until 150 RUs were obtained. The amount of
loaded peptide was 80 ± 4 fmol/mm² chip surface which corresponds to 141±5
Response Units (RUs). Protein-peptide interaction were measured by injecting serial
dilutions of SOCS-3 over the chip surface at a flow rate of 20 µl/min for one
minute. Before injection of SOCS protein the sensor chip was flushed with BSA
(0.1 mg/ml) at a flow rate of 20 µl/min for 1 min. For measurement of the KD value
the flow rate was enhanced to 100 µl/min in order to obtain higher resolution of
kinetics. For this type of experiment SOCS-3 (up to 30 µM) was injected for 3
minutes, dissociation time was 5 minutes, regeneration of the chip between the
measurements in all experiments performed was done at 20 µl/min with 1 M NaCl
in 50 mM NaOH for 30 seconds. To correct for nonspecific binding events an empty
sensor surface without peptide was analyzed in parallel. Thioredoxin (TRX) was
injected at high concentrations (3.5 µM) to rule out unspecific interactions of the
fusion protein of SOCS-3. Data were plotted with subtracted unspecific binding.
Determination of the dissociation constant was done by Scatchard analysis 61.
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2.10 Crystallization of SOCS-3
To crystallize SOCS-3 the method of the hanging drop was chosen. For each
crystallization condition 1 ml of crystallization buffer was pipetted into a reservoir of
a 24 well microtiter plate (Greiner, Solingen, Germany, Cat.# 662160) and
incubated for 30 min for temperature adaptation. Then, highly concentrated
(14 mg/ml) protein was mixed with equal amounts of the respective crystallization
buffer and pipetted onto a siliconized coverslip. Alternatively, protein solution was
mixed with a phosphotyrosine peptide solution comprising tyrosines 429 and 431 of
the human EpoR. The molar ratio between peptide and SOCS-3 protein in these
experiments was 2:1. The coverslip was then inverted and tapped on the reservoir
and finally sealed with vacuum grease in order to prevent rapid evaporation. Crystal
screens were put into a styrofoam box in order to have stable temperature and
humidity conditions and stored in a climatized room at 20°C. Drops were examined
at different time points ranging between 1 day and several months. Precipitants
used were: Crystal Screen, Crystal screen2, Grid Screen PEG6000, Grid Screen
Ammonium Sulfate, Grid Screen 2-Methyl-2,4-pentanediol and Crystal Screen Lite
(Hampton Research, Laguna Nigues, USA).
2.11 High-throughput screening assay for SHP-1
In order to establish a high throughput screening (HTS) assay for SHP-1 in
microtiter plates a generic fluorogenic substrate for alkaline phosphatases, namely
fluorescein-diphosphate (FDP), was used. FDP is a fluorogenic alkaline phosphatase
substrate which is about 50 times more sensitive than the conventional
chromogenic substrate, p-nitrophenyl phosphate. FDP contains two phosphate
groups which quench the fluorescence signal. After hydrolysis of the phosphate
groups, which follows a two-step reaction, a strong fluorescent signal is generated.
The excitation wavelength was in the range of 490 nm, the emission wavelength of
514 nm, respectively. SHP-1 protein was obtained by bacterial expression and
subsequent purification of the construct pMYZ316. The purity of SHP-1 used in the
assay was greater than 90 %, as determined by SDS-PAGE. The assays were
performed in 96, 384 and 1536 well microtiter plates at RT. For detection of the
fluorescent signal a SPECTRAFluor Plus® (Tecan, Crailsheim, Germany) was used.
Amounts of SHP-1 in the assays were in the range of 2.3 pM.
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Assay buffer: 30 mM Tris/HCl
75 mM NaCl
1 mM DTT
0.33 % BSA
pH 7.5
2.12 Methods of cell biology
2.12.1 Transient transfection of cells
For transfection experiments either Lipofectamine Plus (Life Technologies,
Karlsruhe, Germany) or FuGene (Roche, Mannheim, Germany) were used as
transfection reagent, depending on the cells transfected. Transfection procedures
were performed following the manufacturer’s instructions. For transfections cells
were seeded out on 6 cm dishes at a density of approximately 1 × 105 cells/well. For
transfection of the cells one day later, 2 µl of FuGene reagent were dropwise added
to 98 µl of serum-free culture media. Following an incubation time of 5 min 1 µg of
DNA was then added. The ratio of FuGene reagent (µl) to DNA (µg) was always 2:1.
After an incubation time of at least 30 min the transfection solution was added
dropwise onto the 6 cm dish. 12 hours after transfection media was exchanged,
cells were split and grown for additional 24-48 hours at 37°C, 5 % CO2, 90 %
humidity.
2.12.2 Stimulation of eukaryotic cells
For reporter gene assays, SOCS-3 induction and co-immunoprecipitation
experiments both HEK293 and 293T cells were cultivated in DMEM (Life
Technologies, Karlsruhe, Cat.#: 31966-021), 10 % FCS, 2 mM L-glutamine, 1 mM
sodium pyruvate, 50 U/ml penicillin, 50 µg/ml streptomycin, stimulated with
20 ng/ml G-CSF or 10 U/ml Epo. Depending on the cell type used cells were
cultivated with media lacking FCS for the time spans indicated. For SOCS-3
induction in U937 cells, cells were starved for 2 hours prior to stimulation with G-
CSF. For co-immunoprecipitation experiments cells were directly stimulated for
20 min without starving.
2.12.3 Cell lysis
Adherent cells were grown in 10 cm dishes until 100 % confluency, washed twice
with ice-cold PBS, removed from the dish with a cell scraper and pipetted into
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centrifuge tubes. Following centrifugation for 10 min at 4°C at 300 g cells were
lysed with lysis buffer for 30 min at 4°C, passed three times through a 21gauge
needle and finally cell debris were removed by centrifugation at 10,000 × g for
10 min at 4°C. Suspension cells were centrifuged for 10 min at 4°C at 300 × g,
washed twice with ice-cold PBS, and lysed as described before.
Lysis buffer: 50 mM Tris/HCl
150 mM NaCl
10 mM Sodium orthovanadate
0.5 % Triton X-100
0.5 % NP-40
30 µg/ml Antipain-HCl
50 µg/ml Bestatin
0.05 U/ml Chymostatin
30 µg/ml E-64
5 µg/ml Leupeptin
5 µg/ml Pepstatin
30 µg/ml Posphor-amidon
200 µg/ml Pefabloc
5 µg/ml Aprotinin
pH 7.5
2.12.4 Generation of stable HEK 293 reporter gene cell lines
After transfection of HEK293 cells with pMYZ325 and pMYZ399 as described in
2.12 cells were grown with 100 µg/ml geneticin and seeded at a density of
1 cell/well in 96 well microtiter plates. Media were exchanged every 4 days. Cells
were grown until 90 - 100 % confluency, then two replica plates of each 96 well
mother-plates were split into two replica plates, of which one was stimulated with
20 ng/ml G-CSF. 6 hours after stimulation luciferase signal was measured. Those
cell clones which responded best to G-CSF were selected and cultivated for
subsequent luciferase reporter gene experiments. Similarly, stable cell lines
containing pMYZ325 (G-CSFR wt) and pMYZ479 (G-CSFR/Y729F) or pMYZ480
(G-CSFR/Y704F), were generated. Mutagenesis primers for G-CSFR mutants were:
5'-CCCCACTCTGGTCCAGACCTtTGTGCTCCAGGGGGACCC-3' (Y704F sense),
5'-GGGTCCCCCTGGAGCACAaAGGTCTGGACCAGAGTGGGG-3' (Y704F antinsense,
5'-GGCACCAGCGATCAGGTCCTTTtTGGGCAGCTGCTGGGCAGCCCC-3' (Y729F
sense), 5'-GGGGCTGCCCAGCAGCTGCCCAAAAAGGACCTGATCGCTGGTGCC-3'
(Y729F antisense).
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2.12.5 Stable reporter gene assays
Mock-, GFP, and SOCS-3-transduced HEK293 cells carrying the G-CSFR and a
STAT luciferase response element were seeded out on a 96 well microtiter plate at a
density of 1 × 103 cells/well and incubated overnight. HEK293 cells were cultivated
in DMEM (see 2.12) and stimulated with G-CSF at a concentration ranging from
0.2 pg/ml to 1 µg/ml with a serial dilution factor of 4. Luciferase activity was
measured 6 hours after stimulation in a luminometer by lysing the cells with equal
amounts of 2× luciferase buffer. The stimulation factor was calculated by dividing
the signal of stimulated cells through the signal of unstimulated cells. Luciferase
assays with G-CSFR mutants were performed similarly.
2× luciferase buffer: 5 mM ATP
1 mM Luciferin
0.1 mM CoenzymeA
20 mM Tricine
2.7 mM MgSO4
30 mM DTT
0.2 mM EDTA
pH 7.8
2.12.6 Immunoprecipitation
Cells of one 10 cm dish with a confluency of 90 - 100 % were washed twice with ice-
cold PBS and lysed as described in 2.14. To each tube 20 µl of protein G agarose
beads (50 % slurry) were added and incubated at 4°C for 1 hour on a rotation
apparatus in order to remove non-specifically bound proteins. After centrifugation
the supernatant was transferred into a fresh tube and 25 µl of protein G agarose
beads (50 % slurry) as well as 2 µg of antibody was added to each lysate. The
reactions were incubated at 4°C overnight on a rotation apparatus, washed three
times for 2 min with wash buffer (see 2.11). After removal of the supernatant the
precipitates were resuspended in 25 µl 2× Laemmli buffer and boiled at 95°C for
5 min. Samples were run on a polyacrylamide gel and transferred onto a PVDF
membrane (Stratagene, Heidelberg, Germany) for subsequent western blot analyses
(2.3.6).
Endogenous co-immunoprecipitation of SOCS-3 with the G-CSFR
In order to co-immunoprecipitate endogenous G-CSFR with endogenous SOCS-3,
U937 cells were rested in serum-free medium for 4h and then stimulated with 50
ng/ml G-CSF for the times indicated. 4µM proteasome inhibitor MG132 and 100nM
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Na3VO4 were added 10 min prior to stimulation. The cells were lysed in PBS
containing 0.5% NP-40 supplemented with NaF (50 mM), leupeptin (5 µg/ml),
aprotinin (5 µg/ml), PMSF (1 mM) and Na3VO4 (1 mM) and SOCS-3 was precipitated
with SOCS-3 antibody. Precipitated proteins were resolved by SDS-PAGE and
visualized by Western bot techniques using antibodies to SOCS-3 and G-CSFR.
2.13 Methods of virology
2.13.1 Generation of plasmids for retroviral gene transfer
The retroviral vector pMSCVneo (Clontech, Heidelberg, Germany) was digested with
EcoRI. Then, a PCR-amplified fragment containing the MCS of BlueScriptII KS(+)
(Stratagene, Heidelberg, Germany) was digested with ApoI/EcoRI and ligated into
pMSCVneo. Primers flanking the MCS of BlueScriptII KS(+) were:
sense: 5‘-TTTAAATTTGAATTTGAGCTCCACCGCGGTGGCGGCCGC
antisense: 5‘-TTTAAATTTTAGTGGATCCCCCGGGCTGCAGGAATTC
pMSCVneo was then digested with BglII/AccI and PCR-amplified fragment
comprising a IRES-EGFP-ZEO sequence was ligated BamHI/AccI into the MSCV
backbone. PCR primers for the IRES-EGFP-ZEO fragment were:
sense: 5‘-TTTAAATTTGTCGACTCAGTCCTGCTCCTCGGCCACGAAGT
antisense: 5‘-TTTAAATTTGGATCCAATATTTAAATACCATGGCAATTGGAT
This construct was named pMYZ404 (2.1.3). pMYZ387 was generated by ligating
the cDNA of human SOCS-3 into pMYZ404 (BamHI/EcoRI). The cDNA fragment was
generated by PCR and contained 6 nucleotides upstream of the start ATG a Kozak-
sequence for better translation in eukaryotes 62.
2.13.2 Generation of stable virus producing cells
EcoPhoenix cells were seeded into a 10 cm dish at a density of 1 × 105 cells/well
and were transfected with 10 µg DNA and 30 µl of FuGene transfection reagent (see
2.12), according to the manufacturer’s recommendations. When cells were 100 %
confluent, media were exchanged and virus particles were harvested after 12 hours.
Viral supernatants were passed through a 0.22 µM PVDF filter (Millipore,
Eschweiler, Germany) to remove cellular fragments and then used for transduction
of PG13 cells, plated at a density of 5 × 104 cells/well in a 12 well plate. For one
transduction reaction 1 ml of viral supernatant was pipetted on the PG13 cells 63
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and protamine (Sigma, Munich, Germany) at a final concentration of 10 µg/ml was
added afterwards. 12 hours after infection media were exchanged and 48 hours
later cells were grown with 100 µg/ml Zeocin for 2 weeks until used for virus
production. Virus titer was determined by infecting 1 × 105 HT-1080 cells/6 cm
dish with each 1 ml of viral supernatant, serially diluted by a factor of 10. 24 hours
after infection HT-1080 cells were grown with 100 µg/ml Zeocin and after 2 weeks
growing clones were counted in order to determine the number of infectious
particles.
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3 Results
3.1 Cloning, expression and purification of SOCS-3
To investigate interactions of SOCS-3 with both the EpoR and the G-CSFR, purified
recombinant human SOCS-3 protein was generated. The cDNA for SOCS-3 was
cloned out of EST#725896 and ligated into the bacterial expression plasmid pET32
(figure 3.1A), the name of this expression plasmid was pMYZ372.
Figure 3.1: SOCS-3 expression and purification. (A) pET32a expression plasmid. (B) SDS-PAGE
showing the induction of SOCS-3 (lane 2) in comparison to uninduced BL21(DE3)RP E.coli (lane 3).
For large scale protein production bacteria from 1 l media were sedimented, lysed and centrifuged
(lane 4) for subsequent affinity chromatography. Lane 5 shows a representative flow-through fraction
and lane 6 SOCS-3 eluted with 50 mM imidazole. The eluted protein was then subjected to gelfiltration
and as a final purification step an anionic exchange chromatography was performed (lane 7). Lane 1
shows molecular weight standards, the corresponding molecular masses are indicated on the left side
of the panel.
Expression was performed in BL21(DE3)-RP E. coli bacteria at 25°C since higher
expression temperatures resulted in the formation of insoluble inclusion bodies. For
optimal protein expression, media were pre-warmed at 37°C, inoculated with an
overnight-starter culture and grown until an OD600 of 0.5. Then, bacterial cultures
were cooled down to 25°C and induced with IPTG at an OD600 of 1.1. Expression
was performed for a period of 4 hours (fig.3.1B, lanes 2 and 3). Approximately
40 mg of SOCS-3 per liter bacterial culture were obtained. For purification of the
His-tagged SOCS-3, sedimented bacteria from 1 L culture were lysed (fig. 3.1B, lane
4) and loaded onto a Ni-IDA column. SOCS-3 was eluted with 50 mM imidazole
(fig.3.1B, lane 6). Following affinity purification SOCS-3 was subjected to
gelfiltration and finally purified to homogeneity via anionic exchange
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chromatography (fig. 3.1B, lane 7). Purified SOCS-3 protein was used for further
experiments.
3.2 Interaction studies of SOCS-3 with the EpoR
3.2.1 A new recruitment site for SOCS-3 on the EpoR
Recently it has been shown that SOCS-3 exerts its inhibitory activity on IL-6
signaling by binding to phosphotyrosine-759 of gp130 44, 45, which is also the
recruitment site for the phosphotyrosine phosphatase SHP2 64. Moreover, it has
been shown that SOCS-3 binds to the recruitment site for SHP-2 of the
erythropoietin receptor 40. To determine the binding affinities of SOCS-3 to the
EpoR, SOCS-3 binding to tyrosine-phosphorylated and non-phosphorylated
peptides of all EpoR tyrosine motifs was investigated. Table 3.1 shows the
sequences of the peptides used in this study.
Peptide Sequence Position Tyrosine
pY343 E H A Q D T pY L V L D K W 337-349 Y343
pY401 S A A S F E pY T I L D P S 395-407 Y401
pY429pY431 T P P H L K pY L pY L V V S 423-435 Y429, Y431
F429pY431 T P P H L K F L pY L V V S 423-435 Y431
pY429F431 T P P H L K pY L F L V V S 423-435 Y429
Y429Y431 T P P H L K Y L Y L V V S 423-435 Y429, Y431
pY443 S G I S T D pY S S G D S Q 437-449 Y443
pY461pY464 S D G P pY S N P pY E N S L 456-468 Y461, Y464
F461pY464 S D G P F S N P pY E N S L 456-468 Y461, Y464
pY461F464 S D G P pY S N P F E N S L 456-468 Y461, Y464
pY479 P L P P S pY V A C S 474-483 Y479
Table 3.1: Biotinylated EpoR peptides used for SPR measurements and peptide precipitation assays.
Tyrosine-phosphorylated peptides are indicated in red, substituted tyrosines or unphosphorylated
tyrosines are indicated in blue.
Peptides with two proximate tyrosine residues were synthesized as double-
phosphorylated or singly substituted with phenylalanine to detect synergistic effects
on SOCS-3 binding. The amino terminal biotinylated peptides were captured on a
SA biosensor chip and the interaction with SOCS-3 was analyzed. As control,
binding of SOCS-3 to an unloaded sensor surface was measured in parallel.
Additionally, in all experiments performed, 3.5 µM thioredoxin was injected onto the
chip to exclude non-specific binding of the fusion protein. As shown in figure 3.2
the previously reported binding of SOCS-3 to phosphotyrosine pY401 40 could be
confirmed. SOCS-3 was also recruited to a peptide containing pY343, a binding site
for STAT5 65. Interestingly however, SOCS-3 showed high affinity binding to a
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phosphopeptide encompassing pY429 and pY431 of the EpoR (figure 3.2A). The
interaction between SOCS-3 and this peptide is phosphorylation-dependent as the
non-phosphorylated peptide Y429Y431 failed to recruit SOCS-3 (figure 3.2A). When
either of these two tyrosines were substituted with phenylalanine, SOCS-3 binding
was significantly reduced (Table 3.2). Apart from the peptides pY343, pY401, pY429
and pY431 none of the other EpoR-tyrosine motifs showed binding to SOCS-3 (data
not shown).
Figure 3.2: (A) Comparison of SOCS-3 binding to pY343, pY401 and pY429pY431 of the human EpoR.
Biotinylated peptides were immobilized on SA chips, the concentration of SOCS-3 was 8.8 µM. (B)
Sensogram showing the interaction of serially diluted SOCS-3 and peptide pY401. SOCS-3 was diluted
2-fold from 8.8 µM to 275 nM. Purified thioredoxin was taken as control for specific binding. Steady
state binding values were taken for Scatchard-analysis for the determination of KD values.
3.2.2 Quantitative analyses of SOCS-3 binding to the EpoR
As SOCS-3 was recruited by both pY401 and pY429pY431 the affinities of the
binding of SOCS-3 to these receptor motifs were determined. It was observed that
SOCS-3 binds with 9-fold higher affinity to pY429pY431 which contains two
proximate phosphotyrosines than to pY401 which has only a single
phosphotyrosine residue (Table 3.2). Figure 3.2B illustrates the concentration-
dependent binding of human SOCS-3 to immobilized pY401 peptide in the range of
0.275 to 8.8 µM. In figures 3.3A and 3.3B, Scatchard plots used to assess the
binding affinities of SOCS-3 to the pY401 and pY429pY431 motifs are shown and
revealed that the dissociation constant KD is around 9.5 µM for the binding of
SOCS-3 to pY401, whereas the pY429pY431 motif bound with a KD of 1.1 µM (Table
3.2). The motif pY429pY431 of the EpoR contains two tyrosine phosphorylation
sites, separated only by one amino acid residue (Table 3.1). In order to differentiate
between these two tyrosines in the context of SOCS-binding the affinities of SOCS-3
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to peptides containing only phosphotyrosine pY429 or pY431, as well as a double-
phosphorylated peptide pY429pY431 were determined. The SPR measurements
demonstrate that the highest affinity binding of SOCS-3 occurred only if both
tyrosine-429 and tyrosine-431 were phosphorylated (figure 3.3B-D and Table 3.2).
Peptide KD [µM]
pY343 >30
pY401 9.5±0.12
pY429pY431 1.1±0.03
F429pY431 4.6±0.02
pY429F431 4.9±0.02
Y429Y431 n.d.
pY443 n.d.
pY461pY464 n.d.
Y461pY464 n.d.
pY461Y464 n.d.
pY479 n.d.
Table 3.2: KD values of the EpoR peptides as determined by Scatchard analysis. Values are indicated
with standard deviation, n.d.: not determined due to lacking interaction with SOCS-3
Figure 3.3: Scatchard analyses of SOCS-3 interaction with EpoR peptides pY401 (A), pY429pY431 (B),
pY429F431 (C), and F429pY431 (D). Plateau values of the binding curves with serial dilutions of
SOCS-3 (30 µM, 15 µM, 7.5 µM, 3.75 µM, 1.9 µM, 0.9 µM) were taken for the calculation of the KD
values.
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3.2.3. Precipitation of SOCS-3 with EpoR peptides
In order to investigate whether SOCS-3 binds to the receptor motifs containing
pY401 and pY429pY431, a peptide precipitation assay was performed with the
biotinylated EpoR-peptides which have been shown to interact with SOCS-3 in the
SPR experiments. The non-phosphorylated peptide Y429Y431 was used as a
control. Equal amounts of whole cell extracts of COS-7 cells expressing SOCS-3
were incubated with the different EpoR-peptides immobilized on NeutrAvidin-
coupled agarose. Subsequently, precipitated SOCS-3 was analyzed by Western
blotting (figure 3.4). SOCS-3 was found to specifically interact with the tyrosine
motifs pY401 and pY429pY431. pY429pY431 was more potently recruiting SOCS-3
than pY401, reflecting the high affinity binding determined by SPR.
Figure 3.4: SOCS-3 selectively binds to tyrosine-phosphorylated peptides corresponding to the pY401
and pY429pY431 motifs of EpoR. COS-7 cells were transfected with an expression vector for human
SOCS-3 (5 µg). 36 h after transfection cellular extracts were prepared and incubated with biotinylated
peptides corresponding to the EpoR motifs encompassing Y343, Y401 and Y429Y431 immobilized on
NeutrAvidin-coupled agarose. After precipitation the proteins were subjected to Western blot analysis
using a polyclonal SOCS-3 antibody to detect coprecipitated SOCS-3.
The non-phosphorylated peptide Y429Y431 failed to precipitate SOCS-3 as did the
phosphopeptide containing pY343 of the EpoR. This shows that the interaction is
phosphorylation- and sequence-dependent. Single phosphorylated peptides of the
motif encompassing tyrosines Y429 and Y431 in which one of the tyrosines has been
exchanged to phenylalanine (pY429F431 and F429pY431) also readily precipitated
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SOCS-3, although to a lesser extent than the double phosphorylated peptide. The
single phosphorylated peptides were found to precipitate SOCS-3 with comparable
efficiency. This indicates that both phosphotyrosines take part in the interaction
with SOCS-3 and act synergistically. Based on these findings a model structure was
generated (figure 4.1) to better understand the interaction between the SH2 domain
of SOCS-3 and the EpoR. To evaluate this model several point mutations in the SH2
domain of SOCS-3 with subsequent peptide precipitation assays were performed.
Figure 3.5 The SOCS-3 point mutations G53V, L93A and R94E affect the binding to phosphotyrosine
peptides. 293T cells were transfected with an expression vector for wild-type SOCS-3 or SOCS-3
mutants (5 µg). 36 h after transfection cellular extracts were prepared and incubated with biotinylated
peptides immobilized on NeutrAvidin-coupled agarose. After precipitation the proteins were subjected
to Western blot analysis using a polyclonal SOCS-3 antibody to detect coprecipitated SOCS-3.
Detection of total cell lysates (TCL) with a SOCS-3 antibody was used to check the expression levels of
the different mutants. (A) Precipitation of SOCS-3 wt or the SOCS-3 point mutations G53V, L58A,
L93A and R94E with the peptide pY429pY431 (pYpY). (B) Precipitation of SOCS-3 wt or SOCS-3 R94E
with the peptides pY429pY431 (pYpY), F429pY431 (FpY) and pY429F431 (pYF).
Peptides used for precipitation were pY429pY431, F429pY431 and pY429F431.
Figure 3.5A shows that the SOCS-3 mutant L58A, which was predicted not to affect
peptide binding, can be precipitated with pY429pY431 to the same extent as wild-
type SOCS-3. The point mutations R94E, L93A and G53V expected to play a role in
peptide recognition all impair SOCS-3 precipitation with R94E and G53V most
strongly affecting the interaction between SOCS-3 and pY429pY431 (figure 3.5A).
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To better assess the binding mode of the peptides pY429pY431, pY429F431 or
F429pY431, a peptide precipitation assay with wild-type SOCS-3 or the SOCS-3
R94E mutant (figure 3.5B) was performed. Again it was found that the mutation of
arginine 94 to glutamic acid strongly affects the interaction of SOCS-3 with the
double phosphorylated peptide pY429pY431 (pYpY). In comparison, the mutation
only marginally reduces the interaction with the single phosphorylated peptides
pY429F431 (pYF) and F429pY431 (FpY), suggesting that both phosphotyrosines
bind to the phosphotyrosine binding pocket of the SH2 domain with R94 only
playing a minor role in the binding of these peptides.
3.3 Cloning, expression and purification of SHP-1
The cDNA for human SHP-1 was obtained by PCR-cloning from two EST clones
which contained the partial sequence of SHP-1 and was ligated into pET32a.
Several clones were induced with IPTG and the clone expressing highest amounts of
SHP-1 was chosen for quantitative protein expression (figure 3.6A, lanes 2 and 3).
1 L bacterial cultures were sedimented, lysed, and soluble supernatant (figure 3.5A,
lane 6) was taken for affinity chromatography (figure 3.6B). SHP-1 could be purified
to at least 85 % homogeneity as assessed by SDS-PAGE and subsequent Western
blotting (figure 3.6A, lane 8+9) with this single-step purification method. The yield
of 1 L bacterial cultures was approximately 40 mg protein.
Figure 3.6 Expression and purification of SHP-1. (A) SDS-PAGE showing the induction of SHP-1 (lane
2) and uninduced E.coli bacteria carrying SHP-1 (lane 3). An empty vector was similarly induced (lane
4) and not induced (lane 5). After lysis the supernatant (lane 6) was loaded onto a metal chelat column
for affinity purification. Collected flow-through fractions are shown in lane 7, purified SHP-1 is shown
in lane 8. Western blot analysis confirmed SHP-1 as being the protein detected with Coomassie®
staining (lane 9). (B) Chromatogram of the affinity purification of SHP-1. SHP-1 starts eluting at 15 %
puffer B which corresponds to 75 mM imidazole.
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3.4 Development of a high-throughput assay for
SHP-1
To enable high-throughput screening for a possible inhibitor of SHP-1, a
biochemical test system which can be run in 384 or even in 1536 well microtiter
plates was developed. Fluorescence was the read-out of this assay and as generic
substrate fluorescein diphosphate (FDP) was chosen (figure 3.7A). In a rapid two-
step reaction the two quenching phosphate groups are hydrolyzed resulting in a
fluorescent signal.
Figure 3.7 High-throughput screening assay for SHP-1. (A) Hydrolysis of FDP to Fluorescein. (B)
Graph showing initial substrate cleavage velocity of SHP-1 versus different FDP concentrations. C
Lineweaver-Burk plot used for determination of Km.
Since hydrolysis of one phosphate group gives only little fluorescence the reaction
was adopted to a single-step reaction for subsequent Km value calculations.
Therefore, calculated Km values were taken as apparent Km since it was not possible
to distinguish between the single dephosphorylated and the double
dephosphorylated substrate. Figure 3.7B shows the dependence of the initial
velocity of SHP-1 hydrolysis on the substrate concentration. Maximal velocity (Vmax)
could not be reached due to solubility problems of FDP. For determination of the
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Km, curves were linearized and by means of a Lineweaver-Burk plot a Km value of
11.5 µM was calculated (figure 3.7C). To verify this result an additional Eadie-plot
was performed which resulted in a similar Km of 11.2 µM (not shown). This assay
was finally used for high-throughput screening of inhibitory compounds at Bayer
Inc.
3.5 SOCS-3 crystallization
3.5.1 Purification of SOCS-3 for crystallization
For the crystallization of SOCS-3 high concentrations of the protein devoid of the
thioredoxin fusion protein were needed. Similar to the expression and purification
scheme for SPR measurements SOCS-3 was purified in a first step by means of
affinity chromatography. Elution of the protein was achieved at 50 mM imidazole
(fig.3.8A, lane 4). To obtain large amounts of SOCS-3, expression was performed for
4-5 hours at 25°C, a subsequent SDS-PAGE analysis of bacterial lysates and
supernatants revealed that the majority of protein was in a soluble state (figure
3.8A, lanes 1 and 2). After affinity chromatography a buffer exchange was done by
means of gel filtration to enable the cleavage of thioredoxin from SOCS-3 (for buffer
see: 2.3.8). The amount of enterokinase was adjusted to the amount of SOCS-3
protein, the ratio of SOCS-3 to enterokinase was 200 : 1, incubation was performed
at 20°C for 6 hours (figure 3.8A, lane 5). Immediately after digestion the protein
solution was purified by means of cationic exchange chromatography. In this
purification step we took advantage of a change in the pKI of SOCS-3 after removal
of thioredoxin which allowed the direct separation of SOCS-3 and thioredoxin
(figure 3.8A, lane 6). The fusion protein did not even bind to the column and could
therefore be found in the flow-through fraction, while SOCS-3 bound to the matrix.
Elution was performed with only two column volumes in order to concentrate
SOCS-3 for subsequent gel filtration (figure 3.8A, lane 7). In a final step SOCS-3
was concentrated up to 14 mg/ml. This protein solution was used to set up
crystallization screening assays. Additionally, the protein was analyzed by gel
filtration (figure 3.8B) which revealed the formation of SOCS-3 dimers (figure 3.8B,
I). However, the major part of the protein did not dimerize (figure 3.8B, II).
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Figure 3.8 Purification of SOCS-3 for crystallization. (A) SDS-PAGE showing the steps of SOCS-3
purification. Lane 1: Low molecular weight standards (Biomol); Lane 2: Bacterial cell lysate from 1 L
bacterial culture; Lane 3: Supernatant of 1 L bacteria culture; Lane 4: SOCS-3-TRX fusion protein
eluted from Ni-IDA column; Lane 5: Digestion of SOCS-3 with enterokinase for cleavage of the fusion
protein; Lane 6: Cationic IEX after enterokinase digestion; Lane 7: Gelfiltration of SOCS-3 after
cationic IEX; Lane 8: Concentration of SOCS-3 for crystallization. (B) Chromatogram showing
concentrated SOCS-3 ready for crystallization (Lane 8). I: SOCS-3 dimer, II: SOCS-3 monomer, III:
thioredoxin
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3.5.2 Cloning, expression and purification of truncated
SOCS-3
Since the full-length protein (figure 3.9A) was degraded after several weeks of
storage at 4°C a truncated SOCS-3 mutant (figure 3.9B) was generated by
mutagenesis-PCR and then similarly expressed in pET32a(+). Amino-terminal
sequencing of wtSOCS-3 revealed the lack of the first 22 aa after several weeks of
storage. These 22 aa do not correspond to a known domain structure and have
been suggested to form a loop which can easily be cleaved off by proteases because
of its accessibility. Therefore, it was suggested that a mutated SOCS-3 (∆SOCS-3)
Figure 3.9 SOCS-3 proteins expressed and purified. (A) wild-type SOCS-3. (B) truncated SOCS-3
(∆SOCS-3) lacking N-terminally 22 amino acids.
lacking the first 22 aa residues exhibits enhanced protein stability. This ∆SOCS-3
was generated and the expression and purification of this protein was done under
the same conditions as for wtSOCS-3. However, total amounts of SOCS-3 protein
were reduced and the cleavage of TRX from SOCS-3 was achieved only at 30°C with
an incubation time of 10 hours. The expression and purification of ∆SOCS-3 is
shown in figure 3.10. Despite the lack of the first 22 aa the cleaved SOCS-3 protein
was not more stable than the wild-type SOCS-3 (figure 3.10, lane 10). The
concentrated protein (figure 3.10, lane 10) was used for crystallization; for this
purpose 500 different crystallization conditions with and without a peptide
(pY429pY431) were assayed. Once crystallized, the three-dimensional structure will
be determined at the E.M.B.L. Outstation (Grenoble/France) in cooperation with Dr.
Christoph Mueller. So far no crystal formation could be observed but further
experiments are currently ongoing to overcome these problem.
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Fig. 3.10 ∆SOCS-3 expression and purification. Lane 2: Induced BL21(DE3)-RP E.coli with 1mM IPTG;
Lane 3: Uninduced E.coli; Lane 4: Bacterial cell lysate from 1 L bacterial culture; Lane 5: Supernatant
of 1 L sedimented and lysed bacterial culture; Lane 6: Eluted ∆SOCS-3 after affinity chromatography;
Lane 7: Enterokinase digestion of ∆SOCS-3; Lane 8: ∆SOCS-3 after cationic exchange
chromatography; Lane 9: Gel-filtrated ∆SOCS-3; Lane 10: Concentrated ∆SOCS-3 used for
crystallization. I: SOCS-3 dimer, II: SOCS-3 monomer, III: thioredoxin
3.6 Role of SOCS-3 in G-CSF signal transduction
3.6.1 G-CSF rapidly induces SOCS-3 mRNA in  the monocyte
precursor cell line U937 and polymorphonuclear neutrophils
To investigate the role of SOCS-3 in G-CSF signaling SOCS-3 mRNA induction was
analyzed in the human myeloid precursor cell line U937 that endogenously
expresses the G-CSFR. SOCS-3 mRNA induction in these cells was monitored by
RT-PCR. Figure 3.11A shows that although SOCS-3 mRNA is already constitutively
expressed in U937 cells, stimulation with G-CSF leads to an immediate increase in
SOCS-3 mRNA with the expression peaking around 45 min after stimulation. The
mRNA levels then gradually decline and return to nearly basal levels within three
hours. In parallel the induction of other members of the SOCS-family, namely CIS,
SOCS-1 and SOCS-2 was checked. As shown in figure 3.11A, SOCS-1 is also
induced by G-CSF, with mRNA levels peaking around 60 min after stimulation. CIS
and SOCS-2 mRNA are not regulated by G-CSF. To further investigate whether G-
CSF also induces SOCS-3 in freshly isolated polymorphonuclear neutrophils (PMN)
the PMN fraction of healthy donors was stimulated with G-CSF. It was observed
that G-CSF also strongly induces SOCS-3 mRNA in these primary cells with similar
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induction kinetics as in U937 cells. As seen in U937 cells G-CSF also induced
SOCS-1 mRNA in neutrophils (figure 3.11B). SOCS-2 and CIS mRNA was not found
to be regulated by G-CSF in these cells (data not shown).
Figure 3.11 Induction of SOCS-3 mRNA by G-CSF. (A) U937 cells  or (B) polymorphonuclear
neutrophils (PMN) were stimulated with 50 ng/ml G-CSF for 180 min. Samples were taken for the time
points indicated. RT-PCR was performed with 1 µg of total mRNA using primer pairs specific for
human SOCS-3 and human GAPDH as a control. The PCR products were separated by a 2% agarose
gel electrophoresis and visualized by ethidium bromide staining.
3.6.2 SOCS-3 and SOCS-1 inhibit G-CSF receptor-mediated
signal transduction
It has been previously demonstrated that SOCS-3 acts on IL-6 signal transduction
by binding to pY759 of gp130 44, 45 and as the G-CSFR is closely related to gp130 it
was important to determine whether there is a similar inhibitory mechanism
mediated by SOCS-3 in the case of the G-CSFR. First the effect of SOCS-3 on G-
CSF induced signal transduction was investigated. For this purpose, HEK293 cells
were stably transfected with cDNAs encoding G-CSFR and a STAT1, 3, 5-responsive
elment-luciferase construct. Then, these cells were retrovirally transduced with a
construct coding either for green fluorescent protein (GFP) or SOCS-3. Cells were
stimulated with G-CSF and luciferase activity was measured after 6 hours. The
dose-response curves in figure 3.12A clearly demonstrate the inhibitory effect of
SOCS-3 on the STAT response causing a depression of the maximal response to G-
CSF by 74%. The control experiment with cells transduced with a vector containing
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GFP alone gave a similar dose-response curve as the mock-transduced cells and the
same response was maintained.
As it was demonstrated that G-CSF induces both SOCS-3 and SOCS-1 the effect of
SOCS-1 on G-CSF signal transduction was additionally investigated. Figure 3.12C
shows that SOCS-1, like SOCS-3, impairs G-CSF induced STAT3 phosphorylation.
It was also shown that SOCS-1 inhibits the STAT-mediated induction of gene
expression after G-CSF in a reporter gene assay (figure 3.12B).
Figure 3.12 Effect of SOCS-1 and SOCS-3 on G-CSFR mediated signal transduction. (A) Mock-, GFP-,
and SOCS-3-transduced HEK293 cells carrying the wild-type G-CSFR and a STAT luciferase response
element were stimulated with G-CSF at concentrations ranging from 0.2 pg/ml to 1 µg/ml with a
serial dilution factor of 4. Luciferase activity was measured 6 hours after stimulation. The stimulation
factor was calculated by dividing the signal of stimulated cells through the signal of unstimulated
cells. One representative experiment out of 4, with n=8 wells per group is shown. Luciferase response
at maximal G-CSF concentration was set to 100 percent and the percentage of stimulation at maximal
GCSF was calculated. One representative experiment out of 4, with n=8 wells per group is shown. (B)
HEK293 cells carrying the wild-type G-CSFR and a STAT luciferase response element were either
mock-transfected or transfected with different amounts of SOCS-1 cDNA, stimulated with 50 ng/ml G-
CSF for 6 hours and then luciferase activity was measured. One representative experiment out of 4,
with n=8 wells per group is shown. (C) HEK293 cells carrying the wild-type G-CSFR and a STAT
luciferase response element were transiently transfected with a SOCS-3 construct or a myc-tagged
SOCS-1 construct and stimulated with 50 ng/ml G-CSF for 10 minutes. Total cell lysates were
resolved by SDS-PAGE and subjected to Western blot analysis using specific antibodies for phospho-
STAT3, STAT3 and SOCS-3 or a myc-antibody (SOCS-1).
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The dose-response curves in figure 3.12A clearly demonstrate the inhibitory effect of
SOCS-3 on the STAT response causing a depression of the maximal response to
G-CSF by 74%. The control experiment with cells transduced with a vector
containing GFP alone gave a similar dose-response curve as the mock-transduced
cells and the same maximal response was maintained.
3.6.3 SOCS-3 is recruited to the G-CSFR upon stimulation
SOCS-3 was initially shown to inhibit Jak/STAT signaling by binding to and
inhibiting Janus kinases 32-34. It is known that SOCS-3 exerts at least part of its
Figure 3.13 SOCS-3 associates with the activated G-CSFR. HEK293 cells stably expressing the
G-CSFR were either mock-transduced or transduced with SOCS-3, non-stimulated or stimulated with
20 ng/ml G-CSF for 20 min and lysed. Lysates were either immunoprecipitated with antibodies raised
against the G-CSFR and then probed with a SOCS-3 antiserum and vice versa. (A) Co-
immunoprecipitation of SOCS-3 by a G-CSFR antibody. (B) Co-immunoprecipitation of the G-CSFR
with an antiserum raised against SOCS-3. Re-probing of the precipitates was performed in all
experiments to demonstrate equal loading of protein amounts. (C) Coprecipitation of endogenous
G-CSFR with endogenous SOCS-3 in U937 cells stimulated with 50 ng/ml G-CSF. SOCS-3 was
immunoprecipitated as described in Materials and Methods and the co-immunoprecipitated receptor
was detected with a G-CSFR antibody. c: Sepharose control (without antibody)
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inhibitory action through binding to cytokine receptor phosphotyrosine motifs 40, 44,
45, 66-68. Therefore it was investigated whether SOCS-3 is also recruited to the G-CSF
receptor. In order to study possible interactions of SOCS-3 with the G-CSFR, co-
immunoprecipitation experiments were performed in HEK293 cells stably
transfected with G-CSFR and SOCS-3 or G-CSFR alone. Figure 3.14 shows that
both proteins can be readily co-immunoprecipitated. Cell lysates from stimulated
and non-stimulated cells either transduced with human SOCS-3 or non-transduced
were incubated with an antibody recognizing epitopes on the human G-CSFR. As
shown in figure 3.13A SOCS-3 associates with the G-CSFR in a stimulation-
dependent manner. Phosphorylation of the G-CSFR was verified by probing the
membrane with an anti-phosphotyrosine antibody. Similarly, figure 3.13B shows
the co-immunoprecipitation of the G-CSFR with SOCS-3. Cell lysates of
HEK/G-CSFR or HEK/G-CSFR/SOCS-3 cells were precipitated with an antibody
raised against SOCS-3 and probed for tyrosine phosphorylation, G-CSFR and
SOCS-3. Co-precipitated G-CSFR could only be detected in cells stimulated with
G-CSF whereas no G-CSFR was detected in non-stimulated cells as well as
HEK293/G-CSFR cell lysates lacking SOCS-3. These data confirm the stimulation-
dependent association of SOCS-3 with the G-CSFR. In order to assess if SOCS-3 is
recruited to the G-CSFR under physiological conditions, we performed co-
immunoprecipitation experiments in U937 cells stimulated with G-CSF. Figure
3.13C shows that endogenous G-CSFR can be co-precipitated with endogenous
SOCS-3 in a G-CSF-dependent manner over a 60 min time course. SOCS-3 protein
expression can already be detected in non-stimulated U937 cells which coincides
with the observation that SOCS-3 mRNA is constitutively expressed in these cells
(figure 3.11A). After stimulation with G-CSF the SOCS-3 protein levels gradually
increase (figure 3.13C).
3.6.4 SOCS-3 directly binds to a phosphotyrosine peptide
corresponding to tyrosine Y729 of the G-CSFR
To determine the binding site for SOCS-3 on the G-CSFR, peptide precipitation
assays were performed with phosphorylated and non-phosphorylated biotinylated
peptides comprising the four tyrosine motifs Y704, Y729, Y744 and Y764 of the
human G-CSFR.
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Peptide Sequence Position Tyrosine
pY704 P T L V Q T pY V L Q G D P 698-710 704
pY729 T S D Q V L pY G Q L L G S 723-735 729
pY744 S P G P G H pY L R C D S T 738-750 744
pY764 T P S P K S pY E N L W F Q 758-770 764
Y704 P T L V Q T Y V L Q G D P 698-710 704
Y729 T S D Q V L Y G Q L L G S 723-735 729
Y744 S P G P G H Y L R C D S T 738-750 744
Y764 T P S P K S Y E N L W F Q 758-770 764
Table 3.3: Biotinylated G-CSFR peptides used for SPR measurements and peptide precipitation
assays. Tyrosine-phosphorylated peptides are indicated in red, substituted tyrosines or
unphosphorylated tyrosines are indicated in blue.
The G-CSFR peptides were incubated with cell lysates from HEK293 cells
expressing the G-CSFR and SOCS-3. The peptides were precipitated with
streptavidin Sepharose and coprecipitated SOCS-3 was visualized by
immunoblotting. Figure 3.14A shows that SOCS-3 preferentially binds to a peptide
Figure 3.14 SOCS-3 associates with peptides containing phosphorylated Y704 and Y729 of the
human G-CSFR. (A) Lysates from HEK293 cells stably expressing SOCS-3 or (B) purified recombinant
SOCS-3 were incubated with biotinylated phosphorylated and non-phosphorylated peptides
comprising one of the four tyrosine motifs of the cytoplasmic part of the G-CSFR. Peptides were
coupled to NeutrAvidin-coupled Sepharose and pulled down. Precipitates were probed with a
polyclonal SOCS-3 antiserum. (C) Lysates from HEK293 cells expressing His-tagged SOCS-1 were
prepared 48 hours after transfection and incubated with biotinylated phosphopeptides corresponding
to the G-CSFR tyrosine motifs. SOCS-1 was detected with a penta-His antibody.
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containing pY729. Small amounts of SOCS-3 were also coprecipitated with the
peptide encompassing pY704. To test whether SOCS-3 directly binds to the G-CSFR
peptides, purified recombinant SOCS-3 was incubated with the biotinylated
peptides linked to streptavidin-coupled Sepharose. Figure 3.14B shows that
purified SOCS-3 readily coprecipitates with the pY729 peptide, demonstrating direct
binding to this motif. Non-phosphorylated peptides did not interact with SOCS-3.
Thus, the direct interaction of SOCS-3 with specific G-CSFR-peptides is
phosphotyrosine-dependent and sequence-specific. Peptide precipitation assays
performed with cells overexpressing SOCS-1 showed no interaction with the
peptides of the G-CSFR (figure 3.14C).
3.6.5 SOCS-3 binds to Y729 within the G-CSFR
To assess the relevance of SOCS-3 binding to phospho-Y729 and -Y704 motifs
within the G-CSFR, G-CSFR mutants were generated where either Y704 or Y729
was substituted with phenylalanine. HEK293 cells which have been transduced
Figure 3.15 pY729 acts as recruitment site for SOCS-3 within the G-CSFR. HEK293 cells stably
transduced or not transduced with SOCS-3 were transfected with either a Y704F or a Y729F G-CSFR
mutant, non-stimulated or stimulated with 20 ng/ml G-CSF for 20 min and lysed. Cell lysates were
used for co-immunoprecipitation experiments with either SOCS-3 antiserum or an antibody against
the human G-CSFR. Precipitates were probed with SOCS-3 antiserum, a phosphotyrosine or a
G-CSFR antibody.
with SOCS-3 or a control vector were then transiently transfected with the mutated
receptors. As shown in figure 3.15, SOCS-3 was co-immunoprecipitated with the
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G-CSFR in a stimulation-dependent manner in cells carrying the mutated receptor
G-CSFR/Y704F. Immunoprecipitation of the mutant receptor G-CSFR/Y729F
however failed to coprecipitate any SOCS-3 protein.
3.6.6 Mutation of pY729 prevents SOCS-3-mediated inhibi-
tion of G-CSF induced gene expression
In order to determine the importance of SOCS-3 recruitment to phosphotyrosine
pY729 for G-CSF induced signal transduction, reporter gene assays were performed
in HEK293 cells that were stably transfected with cDNAs encoding the G-CSFR
point mutations Y704F or Y729F and a STAT1, 3, 5-responsive element-luciferase
construct. The cells were retrovirally transduced with a construct coding either for
green fluorescent protein (GFP) or SOCS-3. Cells were stimulated with G-CSF and
luciferase activity was measured after 6 hours. Reporter assays in cells carrying a
Y704F mutant showed similar suppression of the luciferase signal (figure 3.16A) as
observed with the wild-type receptor (shown in figure 3.12A). The suppressive effect
of SOCS-3 was lost by mutating tyrosine Y729 to phenylalanine (figure 3.16B). The
control experiment with cells transduced with a vector containing GFP alone gave a
similar dose-response curves and the same maximal response as the mock-
transduced cells.
Figure 3.16. Mutation of Y729 suppresses the SOCS-3-mediated inhibition of G-CSFR induced gene
expression. Mock-, GFP-, and SOCS-3-transduced HEK293 cells carrying the G-CSFR mutants Y704F
(A) or Y729F (B), and a STAT response element were stimulated with G-CSF at concentrations ranging
from 0.2 pg/ml to 1 µg/ml with a serial dilution factor of 4. Luciferase activity was measured 6 hours
after stimulation. Luciferase response at maximal G-CSF concentration was set to 100 percent and the
percentage of stimulation at 1 µg/ml GCSF was calculated.
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3.6.7 SOCS-3 binds to Y729 with high affinity
Next, the affinity of the interaction between SOCS-3 and the G-CSFR peptides was
determined. Phosphorylated and non-phosphorylated G-CSFR peptides were
immobilized on SA chips and the interaction with purified recombinant SOCS-3 was
measured by means of surface plasmon resonance. Figures 3.17A and C show the
sensograms of the two phosphopeptides pY729 and pY704 which interacted with
SOCS-3.
Figure 3.17 Determination of the binding affinities for the interaction between SOCS-3 and the
G-CSFR motifs pY729 and pY704, respectively. Biotinylated peptides were immobilized on SA chips,
the concentration of SOCS-3 was 30 µM. (A, C) Sensograms showing the interaction of serial dilutions
of SOCS-3 and the peptides pY704 and pY729, respectively. Purified thioredoxin was taken as control
for specific binding. Steady state binding values were derived for Scatchard-analysis for the
determination of KD values as shown in Table 3.4. (B, D) Scatchard analysis of SOCS-3 interaction
with G-CSFR peptides pY704 and pY729, respectively. Plateau values of the binding curves with serial
dilutions of SOCS-3 were taken for calculation of the KD values. SOCS-3 concentrations taken for KD
calculation were 30 µM, 15 µM, 7.5 µM and 3.75 µM for pY704, and 30 µM, 15 µM, 7.5 µM 3.75 µM
and 1.9 µM for pY729.
The dissociation constants (KD) for these interactions were derived from Scatchard
plots (figures 3.17B and D). The SPR data (table 3.4) revealed KD values of 2.8 µM
for pY729 and 6.8 µM for pY704. For the phosphopeptides pY744 and pY764 higher
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KD values than 30 µM were obtained. Non-phosphorylated peptides which served as
negative controls did not interact with SOCS-3.
Peptide KD[µM]
pY704 6.8±0.0069
pY729 2.8±0.0162
pY744 >30
pY764 >30
Table 3.4 Derived KD values of the phosphorylated G-CSFR peptides as determined by Scatchard
analysis
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4. Discussion
Cytokines trigger and mediate cellular signaling cascades after binding to their
cognate receptors. Epo and G-CSF, which both belong to the group of hematopoietic
cytokines, play crucial roles in the development of hematopoietic progenitor cells.
Two elements shown to be relevant in the down-regulation of cytokine-mediated
signaling cascades are SOCS-3 and the phosphatase SHP-1. For a better
understanding of mechanisms and actions of these proteins in the context of Epo
and G-CSF signal transduction, biochemical as well as cellular approaches have
been chosen.
4.1 Recombinant SOCS-3
The SOCS proteins represent a group of macromolecules involved in the negative
regulation of a plethora of cytokines in a classical feedback loop (reviewed in 69). The
mechanism of inhibition involves the de novo-synthesis of SOCS proteins, followed
by a recruitment to phosphorylated cytoplasmic tyrosine residues within the
activated cytokine receptor which finally leads to abrogation of cytokine-mediated
signal transduction. SOCS proteins are rapidly degraded 70, recent data implicate
the C-terminal SOCS-box in the rapid degradation by the ubiquitin-proteasome
pathway 36, 37, 71, 72. As a member of this family, SOCS-3 was reported to inhibit
signal transduction by binding into the activation loop of the Janus kinases 73 and
meanwhile it is known that SOCS-3 exerts at least part of its effect by directly
binding to activated cytokine receptor subunits like gp130 or the leptin receptor 44,
45, 67, 68. Furthermore, it was shown that SOCS-3 concomitantly associates with both
the EpoR and Jak2 40. To get a deeper insight into SOCS-3 actions recombinant
SOCS-3 was generated and used for biochemical analyses as well as crystallization
experiments. Expression of SOCS-3 was performed in bacteria since SOCS-3 is a
cytosolic protein without posttranslational modifiactions, i.e. glycosylation.
However, a soluble protein could only be obtained at low expression temperatures,
together with a N-terminal fusion protein (figure 3.1A). Maximal protein amounts
were obtained after 4 hours upon  induction with IPTG. Immediately after affinity
chromatography (figure 3.1B, lane 6) imidazole had to be removed since the
presence of this ingredient resulted in protein instability, leading to spontaneous
aggregation of SOCS-3. For biochemical studies the TRX-tag did not have to be
cleaved. Hence, for this type of experiments, an anionic exchange chromatography
was performed and protein was obtained in a concentration of 90-95 % purity
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(figure 3.1B, lane 7) which could be used for subsequent SPR measurements as well
as peptide precipitation assays. For protein crystallization a highly concentrated
SOCS-3 preparation without a fused TRX-protein was required. For that purpose
SOCS-3 was similarly expressed and affinity-purified as for the biochemical
experiments. Since SOCS-3 was not stable  in buffers containing imidazole the
affinity-purified protein was dialyzed into a buffer without imidazole and a pH of 7.2
because enterokinase shows highest activity between pH 7.0 to 8.0. Lowering the
pH had an additional advantage; namely, a cationic exchange chromatography
purification step could be performed immediately after digestion with enterokinase
without buffer exchange. When SOCS-3-TRX was cleaved, pKis of the two separate
proteins shifted from 6.7 (SOCS-3-TRX) to 8.8 (SOCS-3) and 5.6 (TRX), respectively
(table 4.1). Due to the fact that upon cationic exchange chromatography only
proteins with pKis higher  than the pH of the respective chromatography buffer bind
to the matrix, TRX did not bind to the column while SOCS-3 did. SOCS-3 was
subsequently eluted with a steep gradient of NaCl for concentration of the protein
and finally a preparative gel filtration was performed. The last gel filtration step was
performed to remove aggregated protein as well as residual undigested SOCS-3 and
concentrations of up to 14 mg/ml of pure SOCS-3 could be obtained (figure 3.8A,
lane 8); a qualitative gel filtration with freshly isolated protein showed that part of
SOCS-3 is dimerized (figure 3.8B) which was probably due to disulfide bond
formation of cysteine residues 97, 120 and 193.
pMYZ372 pMYZ470
SOCS-3-TRX SOCS-3 TRX SOCS-3-TRX SOCS-3 TRX
kDa 41897 24769 17074 39429 22371 17074
Length (aa) 384 225 159 361 203 159
pKi 6.7 8.8 5.64 6.4 8.2 5.64
Table 4.1 Characteristics of SOCS-3 constructs used for crystallization experiments.
SOCS-3 was found to be gradually degraded within a few weeks of storage at 4°C.
N-terminal sequencing of the fragments revealed that the first 22 N-terminal aa of
SOCS-3 were cleaved off resulting in a loss of molecular mass of 6 kDa. Most
interestingly, the first 22 aa did not match any known protein domain structure
and the KIR of SOCS-3 is supposed to begin at residue 22 (figure 3.9). Therefore, it
is thinkable that the first amino acids do not form a domain structure and based on
this assumption these residues could be highly accessible to proteases. This
hypothesis is corroborated by observations which show further degradation of this
22 aa fragment, suggesting the presence of loop structures known to be highly
4. Discussion                                                                                                                        57
susceptible to proteolytic degradation. Based on this observations a SOCS-3
construct lacking the first 22 aa was created by mutagenesis, expressed and
similarly purified as the full-length SOCS-3 (figure 3.9). However, this protein was
not more stable than the precursor and showed a similar degradation pattern
(figure 3.10, lane 10). Up to 1000 crystallization screens with and without the
phosphopeptide pY429pY431 of the human EpoR were set up with highly
concentrated proteins in order to obtain SOCS-3 crystals. But so far no crystals
suitable for x-ray diffraction analysis were obained. Current experiments are
ongoing to overcome this problem.
4.2 A new recruitment site for SOCS-3 on the EpoR
The cytoplasmic part of the EpoR contains eight tyrosine residues which serve as
recruitment sites for a number of SH2 domain-containing proteins. Among these
are the protein-tyrosine phosphatases SHP-1 and SHP-2 25, 28, the Jak2 and PI3
kinases 19, 74 as well as STAT5, CIS and SOCS-3 31, 40, 75. In order to study binding of
SOCS-3 to the EpoR a biochemical approach by means of SPR measurements was
used. For this purpose, tyrosine phosphorylated and non-phosphorylated peptides
of all eight tyrosine motifs of the human EpoR were immobilized on a sensor chip
and the interaction with SOCS-3 was analyzed. To further validate the obtained
SPR data, in vitro binding assays in eukaryotic cells were performed.
The results from the SPR experiments show that SOCS-3 binds to pY343, pY401,
pY429 and pY431 with different affinities (Table 3.2). The phosphotyrosine peptides
of all the other EpoR tyrosine motifs did not show binding to SOCS-3. In the SPR
experiments the weakest interaction of SOCS-3 was observed with peptide pY343, a
motif that has been previously shown to recruit STAT5 75. The dissociation constant
for this binding event was greater than 30 µM. In this case the exact KD value was
not assessed by Scatchard analysis since the highest SOCS-3 concentration was
30 µM and a calculation by the BiaEvaluation software was not possible since the
sensograms could not be fitted to an ideal binding model. Confirming results were
obtained from peptide precipitation assays, since it was not possible to precipitate
SOCS-3 from cell lysates of COS-7 cells overexpressing human SOCS-3 (Figure 3.4).
This indicates that the pY343 motif does not play a role with respect to SOCS-3
recruitment. In the context of IL-6 signaling, SOCS-3 has been found to act as
potential competitor of SHP-2 for the binding of the same tyrosine Y759 in the
gp130 receptor subunit 44, 45. Additionally, it was recently shown that the binding
site of SHP-2 in the EpoR, Y401 also recruits SOCS-3, which results in the down-
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regulation of the Epo signaling 40. In the present experiments binding of SOCS-3 to
pY401 could be demonstrated, with a calculated KD for this interaction in the range
of 9.5 µM (Table 3.2). Concerning EpoR signaling SHP-2 is suggested to positively
regulate proliferation 76. As it was shown that SOCS-3 binds to the same
phosphotyrosine of gp130 as SHP-2, which negatively regulates IL-6 signaling 44, it
seemed interesting to investigate whether SOCS-3 would likewise compete with
another negative regulator in the EpoR context, namely SHP-1. SHP-1 is closely
related to SHP-2 and is recruited to the pY429pY431 motif of the EpoR after
stimulation, whereas pY429 is the higher affinity binding site for the phosphatase
28. Both pY429 and pY431 are phosphorylated after stimulation with Epo 65.In Epo
signal transduction, SHP-1 has been reported to negatively regulate proliferation
and differentiation of Ba/F3 or SKT6 cells 28, 29. Interestingly, a peptide was found
encompassing the double phosphorylated tyrosine motif pY429pY431 to bind
SOCS-3 with a KD of 1.1 µM, a nine-fold higher affinity than determined for pY401.
Single phosphorylated peptides pY429 and pY431 revealed KD values in the range of
5 µM which suggests a synergistic binding effect. This finding was confirmed by the
use of a peptide precipitation assay. SOCS-3 was co-precipitated with both the
double phosphorylated peptide pY429pY431 as well as the single phosphorylated
peptides, with pY429pY431 precipitating SOCS-3 most potently (figure 3.4). As the
proximity of pY431 to pY429 impedes the simultaneous recruitment of two SOCS-3
SH2 domains to this double tyrosine motif, the two phosphotyrosine residues must
contact the same SH2 domain, thereby both contributing to the high affinity
binding.
Similar co-operative effects of two proximal phosphotyrosine residues have been
reported to increase the binding of the platelet-derived growth factor (PDGF) β-
receptor to the SH2 domain of the Src family kinases 77. Mori et al. found a double
phosphorylated tyrosine motif encompassing tyrosines Y579 and Y581 to recruit and
activate the kinases of the Src family more potently than the corresponding single
phosphorylated motifs. The authors discuss the phosphorylation of tyrosine Y581
creating a more favorable conformation of the sequence surrounding the tyrosines
Y579 and Y581, thereby increasing binding affinity. Interestingly, the EpoR contains
a similar phosphotyrosine arrangement pattern.
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Figure 4.1 Model structure of the SOCS-3 SH2 complexed with phosphotyrosine peptides.
Electrostatic potential maps of the model structure of the human SOCS-3 SH2 domain
complexed with peptides corresponding to the pY401 and the pY429pY431 motifs of the
EpoR as well as the pY759 motif of gp130. Red and blue-colored regions on the structure
surface of the SH2 domain indicate negative and positive charges, respectively. Bound
phosphopeptides are represented as rod models with nitrogen, oxygen, carbon, and
phosphor atoms being colored in blue, red, white, and yellow, respectively. (A) Interaction of
the SOCS-3 SH2 domain with the SFE(pY401)TILDPSS motif of EpoR, (B) with the EpoR
motif HLK(pY429)L(pY431)LVVSS and (C) with the TVQ(pY759)STVVHSG motif of gp130.
The positions of the amino acids of SOCS-3 relevant for the interaction with the peptide is
indicated. This figure was kindly provided by S. Haan, Dept. of Biochemistry, Univ. of
Aachen.
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In order to better evaluate the results obtained in the SPR experiments and the
peptide precipitation assay, a model structure of the human SOCS-3 SH2 domain
complexed with peptides corresponding to the receptor motifs pY401 and
pY429pY431 of the EpoR as well as to the SOCS-3 recruiting motif pY759 of gp130,
was generated (Figure 4.1). Critical positions for the specific binding of SH2
domains to phosphotyrosine motifs are the amino acids surrounding the
phosphotyrosine residues. The C-terminal amino acid residues at positions Y+1 to
Y+5 of bound peptides have been shown to be important for the interaction with
SH2 domains, with positions Y+1 and Y+3 having the greatest impact on the
binding 42, 43. Table 4.2 shows the sequences of several receptor phosphotyrosine
motifs that have been shown to bind SOCS-3 (40, 44, 45, 67, 68 and this study). Based on
the model structure, the residues involved in specific binding of to the SOCS-3 SH2
domain (Table 4.2) were determined. Positions Y-2, Y+1, Y+3, Y+4 as
Receptor pY Sequence Ref.
h-gp130 pY759 S T V Q pY S T V V H S G 44, 45
h-EpoR pY401 A S F E pY T I L D P S S 40
h-EpoR pY429 P H L K pY L pY L V V S D 78
m-LeptinR pY985 P S V K pY A T L V S N D 67, 68
m-LeptinR pY1077 K S V C pY L G V T S V N 67
h-G-CSFR pY729 D Q V L pY G Q L L G S P 79
consensus sequence:
with h = hydrophobic residue
h x pY h x L h h
S V
T
position relative to pY: -2 0 +1 +2 +3 +4 +5
h-G-CSFR pY704 L V Q T pY V L Q G D P R
Table 4.2 Sequence comparison of pY729 and pY704 with receptor phosphotyrosine motifs
known to recruit SOCS-3
well as Y+5 all contribute to the interaction with residues Y-2, Y+1 and Y+3 being
most crucial for specific binding. This is supported by recent studies on the binding
of SOCS-3 to the gp130 tyrosine motif pY759 where these amino acid residues have
also been found to contribute to the specific recruitment of SOCS-3 45. In regard to
the overlapping binding specificities of SOCS-3 and the two phosphatases SHP-1
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and SHP-2, the position Y-2 of the interacting phosphotyrosine motif seems to play
an important role. Although the two phosphatases bind to different tyrosine motifs
within the EpoR, they are recruited to the same phosphotyrosine pY612 of the
common β-chain in the context of IL-3 signaling 80. A common feature of SHP-1 and
SHP-2 recruiting motifs is a hydrophobic residue at position Y-2 of the binding
phosphotyrosine sequence. It has been shown that this residue is filling a gap
created by a glycine in helix αA within the SH2 domain of the phosphatase 81-84. The
glycine is conserved in the N- and C-terminal SH2 domains of both SHP-1 and SHP-
2 and is required for the unusual involvement of the residue Y-2 of the binding
phosphotyrosine motif 84. Most interestingly, the glycine residue in helix αA of the
SH2 domain is conserved in SOCS-3 and has recently been shown to contribute to
the binding of SOCS-3 to gp130 44. As illustrated in table 4.2, all receptor tyrosine
motifs that have been shown to bind SOCS-3 contain a hydrophobic residue at
position Y-2. The model structure of the SOCS-3 SH2 domain shows that this
residue can easily be fitted into a gap created by G53 of SOCS-3. In regard to the
position Y+1 of the interacting motifs, a hydrophobic residue is suggested to contact
the side chain of K91 or alternatively a small polar residue like serine or threonine
to build up a hydrogen bond with the backbone of the βD-strand to be most
favorable for peptide recognition. For the positions Y+3 to Y+5, a hydrophobic
residue seems optimal for SOCS-3 recruitment with Y+3 contributing most to high
affinity binding.
In order to check the reliability of the model structure several point mutations
within the SH2 domain of SOCS-3 were generated. L58 was mutated which was
predicted not to be involved in peptide binding as well as the residues G53, L93 and
R94 which according to the model contact the peptide positions Y-2, Y+3 and Y+2,
respectively. A peptide precipitation assay confirmed the reliability of the model
structure (Figure 3.5). Whereas L58A does not affect peptide binding, the point
mutation G53V strongly impairs the interaction between SOCS-3 and the peptide.
According to the model structure the valine prevents optimal binding of the peptide
by sterically interfering with the hydrophobic residue at position Y-2 of the
phosphotyrosine peptide. L93 is part of a hydrophobic pocket also involving Y127,
L104 and F136 that accommodates the peptide position Y+3. The fact that the
mutation of leucine 93 to alanine reduces the interaction with pY429pY431 further
confirms the model structure. Arginine 94 is proposed to provide a double contact
with the peptide pY429pY431. First, the side chain builds up a hydrophobic contact
with the aromatic ring of pY429 (contact „h“ in Figure 4.1B) and thereby
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contributes to the binding of pY429 into the phosphotyrosine binding pocket of the
SH2 domain. This interaction is likely to occur for every phosphotyrosine that
accommodates into the classical phosphotyrosine binding pocket of the SOCS-3
SH2 domain and can also be found in other SH2 domains as demonstrated by the
solved structures of Src 85 and SHP2 81 for example. Second, it is postulated that
the positively charged R94 forms a salt bridge with the negatively charged
phosphotyrosine at position Y+2 of the pY429pY431 motif (contact „±“ in Figure
4.1B). The point mutation R94E (which should only marginally affect the interaction
„h“ but would impede the contact „±“) drastically affected SOCS-3 binding to the
double phosphorylated peptide pY429pY431 in the peptide precipitation assay
(Figure 3.5A and B). In contrast the binding of the single phosphorylated peptides
pY429F431 and F429pY431 is only weakly affected by the mutation of arginine 94
to glutamic acid (Figure 3.5B). This indicates that for both peptides the
phosphotyrosine residue binds into the classical phosphotyrosine binding pocket.
The binding of the peptide F429pY431 thus involves a shift of two residues when
compared to the binding mode of pY429pY431 with pY431 binding into the classical
pY-binding pocket and F429 (position Y-2) filling the gap formed by G53 of the SH2
domain. In the context of the activated Epo receptor (and peptide pY429pY431),
Figure 4.2 Elements shown to bind to Y401, Y429 and Y431 of the EpoR. The thickness of the arrows
corresponds to the affinity of the interaction.
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where both tyrosines are phosphorylated, this binding mode would be unfavorable
because of the presence of pY429 at position Y-2. The peptide precipitation assay
with the pY429pY431 motif (Figure 3.5A and B) supports the idea that arginine 94
plays an important role in the recognition of the double phosphorylated motif by
forming a salt bridge with phosphotyrosine pY431.
Based on the identified binding motifs for SOCS-3 and the model structure, a
consensus motif h-X-pY-h/S/T-X-L/V-h-h (with h = hydrophobic) optimal for
SOCS-3 recruitment (see also table 4.2) can be proposed. Remarkably, in the case
of the EpoR motif pY429pY431, pY431 at position Y+2 was found to contribute to
SOCS-3 binding. The plasmon resonance studies, the peptide precipitation assay as
well as the model structures presented in this report, suggest that phosphotyrosine
pY429 binds into the phosphotyrosine binding pocket of the SOCS-3-SH2 domain
between helix αA and the central β-sheet. pY431 appears to increase the binding
affinity by providing an additional contact with the SH2 domain of SOCS-3
involving R94. A conformational change induced by the phosphorylation of tyrosine
Y431 may also contribute to the increase in binding affinity compared to the single
phosphorylated peptide. The positively charged residue (R94 in SOCS-3) in the β−D-
strand is conserved (R/K) in a large number of SH2 domains. As the members of
the Src family also carry a positively charged residue at this position, we favor the
idea that the enhanced binding of Src family kinases to the pY579pY581 motif of
the PDGF β-receptor reported by Mori et al. 77 may be due to the formation of a salt
bridge between pY581 and the lysine residue in the β−D-strand of the SH2 domain
of the Src kinases. The co-operative binding mode that we describe may thus
represent a more general binding mechanism by which SH2 domains achieve high
affinity binding to motifs with proximal phosphotyrosine residues. This would
account for the comparable binding affinities determined for the single
phosphorylated peptides pY429F431 and F429pY431.
The data obtained in this study show that SOCS-3 binds to more than one
phosphotyrosine motif of the EpoR (figure 4.2). As shown by SPR measurements as
well as in vitro binding assays the double phosphorylated motif pY429pY431 in the
EpoR seems to be the preferred binding site for SOCS-3. The implications for the
regulatory proteins SOCS-3, SHP-2 and SHP-1 sharing recruitment sites at the
EpoR (figure 4.2) will be subject to further investigations.
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4.3 A high-throughput screening assay for SHP-1
Drug discovery is a central issue in the pharmaceutical industry and companies are
more and more under pressure to reduce time and costs for finding compounds for
a certain indication. One approach to find such low-molecular weight compounds is
automated high-throughput screening (HTS). In general there are two types of
assays which can be run in a HTS: biochemical and cellular assays. In the first case
a biochemical reaction is performed in microtiter plates with a minimal volume of
6 µl per well. Read-outs can either be fluorescence, chemoluminescence or
radioactivity. Biochemical assays are performed with isolated protein(s) and generic
or specific substrates without a cellular context. In contrast, cellular screening
assays comprise cell lines stably transfected with reporter elements needed for
read-out. These assays take advantage of the utilization of endogenous signaling
elements of the cell, thereby creating a more “physiological” environment. Another
advantage of cellularly-based assays is the possibility to detect cytotoxic
compounds in the first round of screening. Depending on the microtiter plates used
(96, 384, 1536 wells) up to 260,000 compounds can be screened per day  by the
use of computer-controlled pipetting roboters.
The fact that SHP-1 has been shown to be a negative regulator of hematopoiesis 29
makes this enzyme interesting as a potential drug target since an inhibitor of SHP-1
is thought to promote the genesis of erythrocytes and granulocytes. For this
purpose, an enzyme-based, fluorogenic high-throughput screening assay for SHP-1
was developed. Recombinant SHP-1 could be expressed in bacteria and via a single-
step purification scheme high amounts of 80 - 90 % pure protein were obtained
(figure 3.6). Optimization of screening parameters was done in a 96 well microtiter
plate, finally the assay was adapted to a 1536 well format with a final reaction
volume of 9 µl. Parameters which had to be tested before robot screening were
protein stability, protein activity and DMSO compatibility of the test system since
all compounds tested are generally dissolved in DMSO. For this purpose final
concentrations of up to 6.4 % DMSO were added to the reaction buffer, however,
the fluorescence signal only slightly decreased at highest DMSO concentrations.
Furthermore, substrate stability at 4°C had to be determined because all solutions
used for the screening had to be stable for at least one week. Other known
recombinant phosphatases such as PTP--1B, which was commercially available, as
well as recombinant SHP-2, which was cloned and expressed in parallel to SHP-1
(data not shown) served as positive controls for the measurements. The yields of
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SHP-2, however, were very low and as a consequence SHP-2 was used only during
the first steps of optimization.
To detect potential inhibitors of SHP-1 the assay had to be run in the range or
below of the Km of FDP since an excess of substrate leaded to saturation of the
reaction and as a consequence the detection of inhibitors would have been
impossible. Optimal concentrations of FDP for screening were determined and were
in the range of 312 nM, the amount of SHP-1 used was 2.3 pM per well.
4.4 Role of SOCS-3 on G-CSF signal transduction
The G-CSFR is a cytokine receptor responsible for the differentiation and
development of hematopoietic precursor cells into the myeloid lineage, namely
granulocytes and monocytes 86, 87. It was shown that G-CSF, the natural ligand for
the G-CSFR, activates the Jak/STAT- as well as the MAPK-pathway 88-94 but little
was known about the negative regulation of the G-CSF-mediated signal
transduction. It was shown that G-CSF activates the tyrosine phosphatases SHP-1
and SHP-2, the serine/threonine kinase Akt (PKB) as well as SHIP-1 which are
suggested to modulate G-CSF signal transduction 30, 95, 96. SOCS proteins have been
shown inhibit cytokine signaling in a classical feedback loop mechanism 31-34. In
this study the role of SOCS-3 in regard to G-CSF signal transduction was of great
interest since little is known so far concerning the influence of SOCS-3 on G-CSF
signaling. A recent study showed that G-CSF induces SOCS-3 mRNA in bone
marrow cells but the physiological role of this up-regulation is still enigmatic. In a
first step it was investigated whether G-CSF induces SOCS-3 mRNA in the
monocyte precursor cell line U937 as well as in primary polymorphonuclear
neutrophils (PMN). Treatment with human recombinant G-CSF resulted in a
dramatic increase of SOCS-3 mRNA within 45 minutes. This rapid induction of
SOCS-3 was similar to that observed with other cytokines 97-99 and this indicates
that SOCS-3 is an immediate early gene induced by G-CSF to rapidly modulate
G-CSFR-mediated signaling. The strong and rapid induction of SOCS-3 mRNA in
myeloid cells by G-CSF reported here, together with the previously reported potent
induction of SOCS-3 by G-CSF, GM-CSF and IL-3 in bone marrow cells 32, is a
strong indication for SOCS-3 being an important regulator of signal transduction in
immune cells. G-CSF also rapidly induces SOCS-1 mRNA expression in U937 cells
but did not regulate CIS or SOCS-2 mRNA levels (figure 3.11). With the exception of
SOCS-3 the obtained data differ from a previous report where G-CSF was shown to
induce CIS and SOCS-2 but not SOCS-1 mRNA expression in bone marrow cells 32.
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On the other hand induction of SOCS-1 mRNA following treatment with G-CSF has
been shown in the murine myeloid cell line NFS-60 33. This differential induction of
SOCS protein members by G-CSF in different cell types is very interesting and
needs further investigation. STAT1, STAT3 and STAT5 have been shown to be
activated by G-CSF 90, 100, 101. While STAT3 has been linked to myeloid cell
differentiation 102, 103, STAT5 seems to be involved in G-CSF-dependent cell
proliferation 100. Since a potent induction of SOCS-3 mRNA in U937 cells as well as
in primary neutrophils upon G-CSF stimulation was found, the impact of SOCS-3
on G-CSF-induced STAT DNA-binding was examined by means of a STAT-
responsive luciferase assay. In these experiments a significant [p<0001] reduction
in the luciferase activity was observed, suggesting that SOCS-3 acts as a feedback
inhibitor of G-CSF-mediated signal transduction (figure 3.12A and C). A dose
response analysis revealed a suppression of the maximal response in SOCS-3
expressing cells by 74%. In addition it was demonstrated that SOCS-1 also
negatively regulates G-CSF signal transduction (figure 3.12.B and C). Like SOCS-1,
SOCS-3 was initially shown to inhibit Jak/STAT signaling by binding to and
inhibiting Janus kinases 32-34. It has been recently shown that SOCS-3 not only
interacts with Janus kinases but exerts at least part of its inhibitory effect by
binding to the phosphorylated IL-6-type cytokine receptor subunit gp130 44, 45.
Since the G-CSFR shares approximately 45 % homology with gp130 and the two
receptors are structurally related to a great extent it was important to determine
whether there is a similar inhibitory mechanism mediated by SOCS-3. Co-
immunoprecipitation experiments were performed and could show that SOCS-3
interacts with the G-CSFR in a stimulation-dependent manner (figure 3.13A and B).
Furthermore, endogenous G-CSFR with endogenous SOCS-3 was co-
immunoprecipitated in a G-CSF-dependent manner, indicating that the interaction
is of physiological relevance (figure 3.13C). This, together with other recent data 40,
66, 67, 68, 84 strongly suggests that recruitment of SOCS-3 to cytokine receptor
phosphotyrosine motifs is required for SOCS-3 to negatively regulate cytokine
signaling.
To identify the recruitment site for SOCS-3 on the G-CSFR, a peptide precipitation
assay was performed, with phosphorylated and non-phosphorylated biotinylated
peptides comprising one of the four tyrosine motifs of the cytoplasmic part of the
G-CSFR. It could be observed that pY729 was the major binding site for SOCS-3
(figure 3.14) and  a KD of 2.8 µM for this interaction was determined. In addition,
pY704 was found to interact with SOCS-3, the calculated KD for this interaction
being around 6.8 µM (figure 3.17). For comparative reasons KD values of the SOCS-
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3/G-CSFR peptide interaction were set into relation with dissociation constants of
known interaction partners of SOCS-3. Similarly, SPR measurements with SOCS-3
and a biotinylated gp130 peptide comprising the binding motif for SOCS-3, namely
pY759 were performed. In these experiments a KD of about 210 nM (Lehmann et al.,
manuscript submitted) was obtained. The determined affinity is in the same range
as the affinity measured in a recent study reporting a KD value of 42 nM for this
interaction 45. The difference may on the one hand be explained by the use of
peptides corresponding to human (pY759 motif, amino acid sequence: βA-
TSSTVQpYSTVVHSG) versus murine gp130 (pY757 motif) 45 and on the other hand
by differences in the experimental conditions used in both studies. The G-CSFR
peptide binds SOCS-3 with about 13-fold less affinity than the pY759 motif of
gp130.
In comparison, SOCS-1, which was also found to be induced by G-CSF, did not
interact with G-CSFR-derived phosphopeptides (figure 3.14C). This corroborates the
established inhibitory mechanism of SOCS-1 through direct binding to the kinases
of the Janus family 33, 34, 104 and emphasizes the difference in the inhibitory
mechanisms of SOCS-1 and SOCS-3. The alignment of the peptide sequence
around the tyrosine motifs Y729 and Y704 of the G-CSFR with known SOCS-3
recruiting motifs (table 4.2) 40, 44, 45, 67, 68, 84 show a strong sequence homology in the
case of the motif pY729 whereas the amino acid sequence around pY704 shares no
homology with the proposed consensus sequence h-X-pY-h/S/T-X-L/V-h-h (with h
= hydrophobic) optimal for SOCS-3 recruitment (110). It is suggested that the
interaction of SOCS-3 and pY704 is artificial and due to the fact that a small
peptide is used in the SPR experiments. In fact, if the sequence of the peptide
pY704 is read from C-terminus to N-terminus („PDGQLV(pY)TQVLTP“) the amino
acid side chains would fit to a SOCS-3 consensus sequence with a hydrophobic
residue at position Y-2 and positions Y+3 and Y+4. Of course, an interaction in
which an SH2 domain binds to an „inverted“ sequence does not occur in the cell,
however, it is suggested that short peptide sequences may be able to adopt such an
artificial binding mode. Therefore, subsequent co-immunoprecipitation experiments
as well as reporter gene assays with either wild-type G-CSFR or the Y704F and
Y729F mutants were performed to clarify the role of the two tyrosine motifs in
regard to the SOCS-3 action in the context of the full length G-CSF receptor and the
cellular environment. A complete loss of SOCS-3 binding upon mutation of Y729
was observed, strongly suggesting that pY729 is the physiological binding site for
SOCS-3 and that pY704 does not play a significant role in recruiting SOCS-3 in the
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context of the full length G-CSF receptor (figure 3.15). Reporter gene assays
performed with the wild-type receptor as well as Y704F and Y729F receptor
mutants revealed that mutation of Y704 has no effect on the suppression of G-CSF
mediated STAT activation by SOCS-3 (figure 3.16A). In contrast, substitution of
Y729 to phenylalanine resulted in luciferase activities similar to those found in
control or mock-transduced cells (figure 3.16B). These data, together with the data
from our co-immunoprecipitation experiments strongly suggest that Y729 of the G-
CSFR is essential for the inhibitory effect of SOCS-3 on G-CSFR mediated signal
transduction. G-CSF is commonly used for the treatment of leukopenias following
chemotherapy or radiation therapy as well as severe congenital neutropenia (SCN)
12, 105. Approximately 10% of SCN patients develop acute myeloid leukemia 106, 107
and a correlation between the acquisition of G-CSFR mutations and the leukemic
progression of the disease has been reported 108-110. These mutations introduce
premature stop codons between codons 714 and 732 and a recent report provides
evidence that a G-CSFR truncated at amino acid position 715 results in sustained
STAT5 activation and a hyperproliferative response in mice carrying this mutation
111. Although a slower internalization rate of the mutated G-CSFR was found in
these mice and could be responsible for this response, it is suggested that the
absence of the SOCS-3 recruiting motif pY729 identified in the present study also
contributes to this increased and prolonged STAT activation.
Taken together, it could be shown that SOCS-3 is strongly and rapidly induced by
G-CSF in myeloid cells and then potently inhibits G-CSFR-mediated signal
transduction. Further evidence is provided that the inhibitory action of SOCS-3 on
G-CSF signaling involves the direct binding of SOCS-3 to the activated G-CSFR and
that phosphotyrosine pY729 was identified as being the major recruitment site for
SOCS-3. To evaluate the implications of SOCS-3 recruitment to the receptor motif
pY729 on the various signaling components involved in G-CSF signal transduction
further studies are necessary and are currently under investigation.
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5. Summary
Erythropoietin and G-CSF are cytokines involved in hematopoiesis. While Epo is
mainly responsible for commitment and differentiation of hematopoietic stem cells
into cells of the erythroid lineage, G-CSF supports the development of
hematopoietic progenitor cells committed to the neutrophil/granulocyte lineage
differentiation granulocytes. Both the EpoR as well as the G-CSFR belong to the
hematopoietic superfamily and both receptors homo-dimerize upon stimulation by
their respective ligands. After dimerization cytokine-specific signaling cascades are
triggered, including the Jak/STAT-pathway. SOCS-3 and SHP-1 have been
demonstrated to be negative regulators of cytokine signaling. In this study the role
of these two molecules in the context of Epo- and G-CSF-mediated signal
transduction was investigated.
As a first step interactions of SOCS-3 with the EpoR were studied since there was
some evidence from the literature that SOCS-3 would bind to more than one
recruitment site on the Epo receptor. For that purpose SOCS-3 was cloned,
expressed and purified for subsequent biochemical experiments, namely peptide
precipitation assays and surface plasmon resonance studies. These experiments
revealed two possible binding sites on the EpoR, however, sequence-homology
alignments as well as a structure model suggest that a double-phosphotyrosine
motif is most important for SOCS-3 binding.
The phosphatase SHP-1 has been shown to be a negative regulator of red blood cell
formation. Furthermore, SHP-1 has been demonstrated to be induced by G-CSF in
granulocytic differentiation. These observations lead to the assumption that this
protein may represent a potential drug target and an inhibitor of this phosphatase
would be expected to promote erythropoiesis and granulopoiesis. Thus, SHP-1 was
cloned, expressed and purified and a biochemical high-throughput screening assay
for detection of low-molecular weight inhibitors was established. At a final stage the
assay was run in a 1536 well microtiter plate format.
To get more insight into the association of SOCS-3 with the EpoR, co-crystallizing
experiments with recombinant SOCS-3 and an EpoR peptide were set up.
Recombinant SOCS-3 was expressed, purified to high purity and concentrated.
Protein concentrations up to 14 mg/ml could be achieved. With these solutions
several hundred crystal screens were set up with the method of the hanging drop.
Once crystallized, the three-dimensional structure of SOCS-3 will be determined by
X-ray diffraction studies at the EMBL in Grenoble.
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Finally, the role of SOCS-3 in regard to G-CSF-mediated signal transduction was
investigated since little was known so far concerning the role of SOCS-3 in G-CSF
signal transduction. It could be shown that SOCS-3 mRNA is induced in the
monocytic precursor cell line U937 as well as in primary polymorphonuclear
neutrophils. Biochemical as well as cellular analyses revealed that SOCS-3
suppresses G-CSF-mediated signal transduction by binding to the G-CSFR in a
stimulation-dependent manner. By means of SPR, peptide precipitation assays as
well as mutational analyses, one tyrosine residue within the receptor could be
addressed of being the major recruiting site of SOCS-3, namely tyrosine 729.
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6. Outlook
From the obtained results in this study several questions have been arising which
will be issue of further investigations.
(1) Does SOCS-3 have an influence on the genesis of erythrocytes and
granulocytes?
SOCS proteins have been shown to be effective inhibitors of cytokine signaling in
the context of various cytokines (Reviewed in 112). Among the members of this family
SOCS-3 mRNA has been shown to be induced in bone marrow cells 32, PMNs 79 and
various precursor cell lines 33,. SOCS-3 protein could be detected in high levels in
fetal livers 39 and the monocyte precursor cell line U937 79. Moreover, SOCS-3
knock-out mice show embryonic lethality associated with erythrocytosis, indicating
its' importance in fetal liver erythropoiesis 39. These data lead to the assumption
that there may be an influence of SOCS proteins in the regulation of hematopoiesis,
i.e. erythropoiesis or granulopoiesis in adults. This assumption is corroborated by
studies showing the association of SOCS family members with the EpoR and the G-
CSFR and the subsequent down-regulation of these signaling pathways 31, 40, 78, 79.
Both Epo and G-CSF are important cytokines having a great impact on the
proliferation and differentiation of precursor cells of both the myeloid and the
lymphoid lineage, therefore, it would be of great interest to elucidate the role of
SOCS-3 in both erythropoiesis and granulopoiesis.
To address this question experiments with hematopoietic precursor cells (CD34+)
overexpressing wt or dominant negative SOCS-3 have to be done with the help of
viral transduction systems since the transfection efficiency of these cells with
conventional transfection techniques is suboptimal. Proliferation as well as the
differentiation status of the cells could be determined by fluorescence-activated cell
sorting (FACS)-analyses, semi-solid cell plating techniques as well as liquid culture
systems. By state-of-the-art co-cultivating techniques with stroma cells a more
physiological environment for the hematopoietic precursor cells could be provided.
(2) Kinetics of SOCS-3 inhibition in the context of G-CSF signaling?
SOCS-3 has been shown to be induced by G-CSF and to regulate G-CSF-mediated
signal transduction 79. Although it could be demonstrated that SOCS-3 associates
with the G-CSFR upon stimulation with G-CSF, the time profile  of inhibition is not
clear. Based on studies on the EpoR 40, 73 it is assumed that SOCS-3 binds on the
one hand to the receptor via its SH2 domain and on the other hand to the receptor-
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associated Jak2 via the KIR. However, it is not known whether this recruitment is
consecutive (initial binding to the receptor followed by binding to Jak2) or
simultaneouos. To answer this question kinetic studies of both Jak and STAT
phosphorylation have to be performed by Western blotting as well as by gel shift
assays.
(3) SOCS proteins as targets for the pharmaceutical industry
There are no data so far  whether SOCS-3 interacts with Jak2 only, or also with
Jak1 and TYK2, which are likewise involved in G-CSF signaling 88, 93, 113. In a recent
study by Nicholson et al. 45 the IC50 values for the interaction of SOCS-3 with Jak1
and Jak2 activation loop-peptides (Jak1: IETDKE(pY)YKVKEPGE; Jak2:
LPQDKE(pY)YKVKEPGE) have been determined, resulting in an IC50 value of
230 µM for Jak1 and 1,200µM for Jak2, respectively. The authors concluded that
there may be no association of SOCS-3 with Janus kinases under physiological
conditions because of the high IC50 values. Activation loops of Jaks, however, have
two proximate tyrosine residues, which can both be phosphorylated upon
stimulation. In the context of Jak2 and SOCS-3 interactions we observe a higher
affinity of SOCS-3 towards Jak2 peptides when both tyrosine residues of the
activation loop, namely Y1007 and Y1008, are phosphorylated. This interaction was
shown to be in a physiological range and therefore it is hypothesized that SOCS-3
indeed binds to Jak2, depending on the phosphorylation state of the activation
loop. To further elucidate these findings phosphorylation studies of Jaks after
G-CSF treatment have to be done. Additional interaction studies with SOCS
domains (SH2, KIR) need to address the binding mode of SOCS-3 towards Jaks.
(4) SOCS proteins as targets for the pharmaceutical industry?
Patients who suffer from leukopenia following chemotherapy, radiotherapy or bone
marrow transplantation are treated with recombinant cytokines such as G-CSF and
Epo to reconstitute cells of the myeloid and erythroid lineage as well as to improve
the immunological parameters. Since the pharmaceutical company AMGEN has all
patents on recombinant G-CSF and Epo and since the market for these products is
a fast-growing one, other pharmaceutical companies have a great interest to develop
either inhibitors against negative regulators of Epo and G-CSF signaling or analogs
of Epo and G-CSF. SOCS proteins have been shown to be  potent negative
regulators of cytokine signaling pathways. Among these proteins SOCS-3 has been
demonstrated to suppress both G-CSF as well as Epo-mediated signal transduction
40, 79. Thus, SOCS-3 could be an interesting target candidate for pharmaceutical
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companies. By inhibiting SOCS-3 both Epo and G-CSF signaling could be
enhanced/attenuated resulting in an increased production of erythrocytes and
granulocytes, an effect highly desirable for patients receiving anti-tumor regimens
such as radiotherapy or chemotherapy. A possible inhibitor of SOCS-3 should
ideally inhibit both the association of the SH2 domain of SOCS-3 with the
respective cytokine receptor as well as the receptor-associated Janus kinase.
Primary screening approaches could be done by means of fluorescence resonance
energy transfer (FRET) or fluorescence polarization assays with the purified SH2
domain of SOCS-3 and receptor/Jak peptides.
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